<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Bull World Health Organ</journal-id><journal-id journal-id-type="iso-abbrev">Bull. World Health Organ</journal-id><journal-id journal-id-type="publisher-id">BLT</journal-id><journal-title-group><journal-title>Bulletin of the World Health Organization</journal-title></journal-title-group><issn pub-type="ppub">0042-9686</issn><issn pub-type="epub">1564-0604</issn><publisher><publisher-name>World Health Organization</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26478625</article-id><article-id pub-id-type="pmc">4581646</article-id><article-id pub-id-type="publisher-id">BLT.14.150516</article-id><article-id pub-id-type="doi">10.2471/BLT.14.150516</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Eliminating artificial trans fatty acids in Argentina: estimated effects on the burden of coronary heart disease and costs</article-title><trans-title-group xml:lang="fr"><trans-title xml:lang="fr">&#x000c9;limination des acides gras trans artificiels en Argentine: effets estim&#x000e9;s sur la charge des cardiopathies coronariennes et sur les co&#x000fb;ts associ&#x000e9;s</trans-title></trans-title-group><trans-title-group xml:lang="es"><trans-title xml:lang="es">La eliminaci&#x000f3;n de los &#x000e1;cidos grasos de tipo trans artificiales en Argentina: efectos estimados en la carga de cardiopat&#x000ed;as coronarias y los costes</trans-title></trans-title-group><trans-title-group xml:lang="ar"><trans-title xml:lang="ar">&#x00627;&#x00644;&#x00642;&#x00636;&#x00627;&#x00621; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00623;&#x0062d;&#x00645;&#x00627;&#x00636; &#x00627;&#x00644;&#x0062f;&#x00647;&#x00646;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x0062a;&#x0062d;&#x00648;&#x00644;&#x00629; &#x00627;&#x00644;&#x00635;&#x00646;&#x00627;&#x00639;&#x0064a;&#x00629; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00623;&#x00631;&#x0062c;&#x00646;&#x0062a;&#x0064a;&#x00646;: &#x00627;&#x00644;&#x00622;&#x0062b;&#x00627;&#x00631; &#x00627;&#x00644;&#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631;&#x0064a;&#x00629; &#x00639;&#x00644;&#x00649; &#x00639;&#x00628;&#x00621; &#x00627;&#x00644;&#x00623;&#x00645;&#x00631;&#x00627;&#x00636; &#x00627;&#x00644;&#x00642;&#x00644;&#x00628;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00648;&#x00639;&#x00627;&#x00626;&#x0064a;&#x00629; &#x00648;&#x00646;&#x00641;&#x00642;&#x00627;&#x0062a;&#x00647;&#x00627; </trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title xml:lang="zh">&#x05728;&#x0963f;&#x06839;&#x05ef7;&#x06d88;&#x09664;&#x04eba;&#x05de5;&#x053cd;&#x05f0f;&#x08102;&#x080aa;&#x09178;&#x0ff1a; &#x05bf9;&#x051a0;&#x05fc3;&#x075c5;&#x08d1f;&#x062c5;&#x053ca;&#x06210;&#x0672c;&#x07684;&#x09884;&#x04f30;&#x05f71;&#x054cd;</trans-title></trans-title-group><trans-title-group xml:lang="ru"><trans-title xml:lang="ru">&#x00423;&#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00438;&#x00441;&#x0043a;&#x00443;&#x00441;&#x00441;&#x00442;&#x00432;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00442;&#x00440;&#x00430;&#x0043d;&#x00441;&#x00436;&#x00438;&#x00440;&#x0043d;&#x0044b;&#x00445; &#x0043a;&#x00438;&#x00441;&#x0043b;&#x0043e;&#x00442; &#x00432; &#x00410;&#x00440;&#x00433;&#x00435;&#x0043d;&#x00442;&#x00438;&#x0043d;&#x00435;: &#x0043e;&#x00436;&#x00438;&#x00434;&#x00430;&#x00435;&#x0043c;&#x0043e;&#x00435; &#x00432;&#x0043e;&#x00437;&#x00434;&#x00435;&#x00439;&#x00441;&#x00442;&#x00432;&#x00438;&#x00435; &#x0043d;&#x00430; &#x00431;&#x00440;&#x00435;&#x0043c;&#x0044f; &#x00438;&#x00448;&#x00435;&#x0043c;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x0043e;&#x00439; &#x00431;&#x0043e;&#x0043b;&#x00435;&#x00437;&#x0043d;&#x00438; &#x00441;&#x00435;&#x00440;&#x00434;&#x00446;&#x00430; &#x00438; &#x0043d;&#x00430; &#x00441;&#x0043e;&#x0043f;&#x00443;&#x00442;&#x00441;&#x00442;&#x00432;&#x00443;&#x0044e;&#x00449;&#x00438;&#x00435; &#x00440;&#x00430;&#x00441;&#x00445;&#x0043e;&#x00434;&#x0044b;</trans-title></trans-title-group><alt-title alt-title-type="author-running-head">Adolfo Rubinstein et al.</alt-title><alt-title alt-title-type="title-running-head">Trans fats in Argentina</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Rubinstein</surname><given-names>Adolfo</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Elorriaga</surname><given-names>Natalia</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Garay</surname><given-names>Osvaldo U</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Poggio</surname><given-names>Rosana</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Caporale</surname><given-names>Joaquin</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Matta</surname><given-names>Maria G</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Augustovski</surname><given-names>Federico</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pichon-Riviere</surname><given-names>Andres</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mozaffarian</surname><given-names>Dariush</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><aff id="aff1"><label>a</label>Institute for Clinical Effectiveness and Health Policy (IECS), Ravignani 2024, Buenos Aires, C1414CPV, <country>Argentina</country>.</aff><aff id="aff2"><label>b</label>Friedman School of Nutrition Science and Policy, Tufts University, Boston, <country>United States of America</country>.</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to Adolfo Rubinstein (email: <email xlink:href="arubinstein@iecs.org.ar">arubinstein@iecs.org.ar</email>).</corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>9</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>23</day><month>6</month><year>2015</year></pub-date><volume>93</volume><issue>9</issue><fpage>614</fpage><lpage>622</lpage><history><date date-type="received"><day>16</day><month>11</month><year>2014</year></date><date date-type="rev-recd"><day>15</day><month>3</month><year>2015</year></date><date date-type="accepted"><day>10</day><month>4</month><year>2015</year></date></history><permissions><copyright-statement>(c) 2015 The authors; licensee World Health Organization.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/igo/legalcode">http://creativecommons.org/licenses/by/3.0/igo/legalcode</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.</license-p></license></permissions><abstract><title>Abstract</title><sec><title>Objective</title><p>To estimate the impact of Argentine policies to reduce trans fatty acids (TFA) on coronary heart disease (CHD), disability-adjusted life years (DALYs) and associated health-care costs.</p></sec><sec><title>Methods</title><p>We estimated the baseline intake of TFA before 2004 to be 1.5% of total energy intake. We built a policy model including baseline intake of TFA, the oils and fats used to replace artificial TFAs, the clinical effect of reducing artificial TFAs and the costs and DALYs saved due to averted CHD events. To calculate the percentage of reduction of CHD, we calculated CHD risks on a population-based sample before and after implementation. The effect of the policies was modelled in three ways, based on projected changes: (i) in plasma lipid profiles; (ii) in lipid and inflammatory biomarkers; and (iii) the results of prospective cohort studies. We also estimated the present economic value of DALYs and associated health-care costs of coronary heart disease averted.</p></sec><sec><title>Findings</title><p>We estimated that projected changes in lipid profile would avert 301 deaths, 1066 acute CHD events, 5237 DALYs and 17 million United States dollars (US$) in health-care costs annually. Based on the adverse effects of TFA intake reported in prospective cohort studies, 1517 deaths, 5373 acute CHD events, 26&#x02009;394 DALYs and US$ 87 million would be averted annually.</p></sec><sec><title>Conclusion</title><p>Even under the most conservative scenario, reduction of TFA intake had a substantial effect on public health. These findings will help inform decision-makers in Argentina and other countries on the potential public health and economic impact of this policy.</p></sec></abstract><trans-abstract xml:lang="fr"><title>R&#x000e9;sum&#x000e9;</title><sec><title>Objectif</title><p>Estimer l'impact des politiques argentines de r&#x000e9;duction des acides gras trans (AGT) sur les cardiopathies coronariennes (CC), les ann&#x000e9;es de vie corrig&#x000e9;es du facteur incapacit&#x000e9; (AVCI) et les co&#x000fb;ts des soins de sant&#x000e9; associ&#x000e9;s.</p></sec><sec><title>M&#x000e9;thodes</title><p>Nous sommes partis d'une estimation de l'apport de r&#x000e9;f&#x000e9;rence en AGT avant 2004 repr&#x000e9;sentant 1,5% de l'apport &#x000e9;nerg&#x000e9;tique total. Nous avons con&#x000e7;u un mod&#x000e8;le pour ces politiques, en int&#x000e9;grant cet apport en AGT de r&#x000e9;f&#x000e9;rence, les huiles et graisses utilis&#x000e9;es pour remplacer les AGT artificiels, les effets cliniques de la r&#x000e9;duction des AGT artificiels, les co&#x000fb;ts associ&#x000e9;s ainsi que les AVCI &#x000e9;pargn&#x000e9;es du fait des accidents coronariens &#x000e9;vit&#x000e9;s. Pour calculer le pourcentage de r&#x000e9;duction des CC, nous avons calcul&#x000e9; les risques de CC sur un &#x000e9;chantillon en population, avant et apr&#x000e8;s la mise en &#x00153;uvre de ces politiques. Les effets de ces politiques ont &#x000e9;t&#x000e9; mod&#x000e9;lis&#x000e9;s de trois mani&#x000e8;res, en fonction des changements projet&#x000e9;s: (i) au niveau des profils lipidiques plasmatiques; (ii) au niveau des biomarqueurs lipidiques et inflammatoires et (iii) en fonction des r&#x000e9;sultats des &#x000e9;tudes prospectives de cohortes. Nous avons &#x000e9;galement estim&#x000e9; la valeur &#x000e9;conomique actuelle des AVCI et du co&#x000fb;t des soins de sant&#x000e9; associ&#x000e9;s correspondant aux cardiopathies coronariennes &#x000e9;vit&#x000e9;es.</p></sec><sec><title>R&#x000e9;sultats</title><p>Selon nos estimations, les changements projet&#x000e9;s des profils lipidiques devraient permettre d'&#x000e9;viter 301 d&#x000e9;c&#x000e8;s, 1 066 accidents coronariens aigus, 5 237 AVCI et 17 millions de dollars des &#x000c9;tats-Unis d'Am&#x000e9;rique ($US) de d&#x000e9;penses annuelles en soins de sant&#x000e9;. &#x000c0; partir des effets d&#x000e9;favorables des apports en AGT indiqu&#x000e9;s dans les &#x000e9;tudes prospectives de cohortes, ce sont 1 517 d&#x000e9;c&#x000e8;s, 5 373 accidents coronariens aigus, 26 394 AVCI et 87 millions de $US de d&#x000e9;penses qui pourraient &#x000ea;tre &#x000e9;vit&#x000e9;s chaque ann&#x000e9;e.</p></sec><sec><title>Conclusion</title><p>M&#x000ea;me dans le sc&#x000e9;nario le plus prudent, la r&#x000e9;duction de l'apport en AGT a un effet consid&#x000e9;rable sur la sant&#x000e9; publique. Ces r&#x000e9;sultats permettront d'informer les d&#x000e9;cideurs en Argentine et dans d'autres pays sur les impacts potentiels de ce type de politiques sur le plan &#x000e9;conomique et en termes de sant&#x000e9; publique.</p></sec></trans-abstract><trans-abstract xml:lang="es"><title>Resumen</title><sec><title>Objetivo</title><p>Estimar el impacto de las pol&#x000ed;ticas argentinas para la reducci&#x000f3;n de los &#x000e1;cidos grasos de tipo trans (AGT) en las cardiopat&#x000ed;as coronarias, los a&#x000f1;os de vida ajustados en funci&#x000f3;n de la discapacidad (AVAD) y los costes de la atenci&#x000f3;n sanitaria asociados.</p></sec><sec><title>M&#x000e9;todos</title><p>Se estim&#x000f3; que la ingesta base de AGT antes de 2004 era de 1,5% de la ingesta de energ&#x000ed;a total. Se construy&#x000f3; un modelo de pol&#x000ed;tica que inclu&#x000ed;a la ingesta base de AGT, los aceites y grasas utilizados para reemplazar los AGT artificiales, el efecto cl&#x000ed;nico de reducir los AGT artificiales y el coste y los AVAD salvados debido a los casos de cardiopat&#x000ed;as coronarias evitadas. Para calcular el porcentaje de reducci&#x000f3;n de cardiopat&#x000ed;as coronarias, se calcularon los riesgos de cardiopat&#x000ed;as coronarias en un modelo basado en la poblaci&#x000f3;n antes y despu&#x000e9;s de la implementaci&#x000f3;n. El efecto de las pol&#x000ed;ticas fue modelado de tres formas, en base a cambios estimados: (i) perfiles de plasma de l&#x000ed;pidos; (ii) marcados biol&#x000f3;gicos inflamatorios de l&#x000ed;pidos; y (iii) los resultados de estudios de cohortes prospectivos. Tambi&#x000e9;n se estim&#x000f3; el valor econ&#x000f3;mico actual de los AVAD y los costes de atenci&#x000f3;n sanitaria asociados a las cardiopat&#x000ed;as coronarias evitadas.</p></sec><sec><title>Resultados</title><p>Se estim&#x000f3; que los cambios estimados en el perfil de l&#x000ed;pidos evitar&#x000ed;an 301 muertes, 1.066 casos graves de cardiopat&#x000ed;as coronarias, 5.237 AVAD y 17 millones de d&#x000f3;lares estadounidenses (USD) en atenci&#x000f3;n sanitaria cada a&#x000f1;o. Bas&#x000e1;ndose en los efectos adversos del consumo de AGT de los estudios de cohortes prospectivos, se evitar&#x000ed;an 1.517 muertes, 5.373 casos graves de cardiopat&#x000ed;as coronarias, 26.394 AVAD y 87 millones de USD cada a&#x000f1;o.</p></sec><sec><title>Conclusi&#x000f3;n</title><p>Incluso bajo el escenario m&#x000e1;s conservador, la reducci&#x000f3;n del consumo de AGT tuvo un efecto sustancial en la salud p&#x000fa;blica. Estos resultados ayudar&#x000e1;n a informar a los responsables de la toma de decisiones en Argentina y otros pa&#x000ed;ses sobre el potencial impacto econ&#x000f3;mico y de salud p&#x000fa;blica de esta pol&#x000ed;tica.</p></sec></trans-abstract><trans-abstract xml:lang="ar"><title>&#x00645;&#x00644;&#x0062e;&#x00635; </title><sec><title>&#x00627;&#x00644;&#x0063a;&#x00631;&#x00636; </title><p>&#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631; &#x00623;&#x0062b;&#x00631; &#x00627;&#x00644;&#x00633;&#x0064a;&#x00627;&#x00633;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00623;&#x00631;&#x0062c;&#x00646;&#x0062a;&#x0064a;&#x00646;&#x0064a;&#x00629; &#x00644;&#x00644;&#x0062d;&#x0062f; &#x00645;&#x00646; &#x00627;&#x00644;&#x00623;&#x0062d;&#x00645;&#x00627;&#x00636; &#x00627;&#x00644;&#x0062f;&#x00647;&#x00646;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x0062a;&#x0062d;&#x00648;&#x00644;&#x00629; (TFA) &#x00639;&#x00644;&#x00649; &#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00642;&#x00644;&#x00628;&#x0064a; &#x00627;&#x00644;&#x00648;&#x00639;&#x00627;&#x00626;&#x0064a; (CHD)&#x0060c; &#x00648;&#x00633;&#x00646;&#x00648;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00639;&#x00645;&#x00631; &#x00627;&#x00644;&#x00645;&#x00635;&#x0062d;&#x0062d;&#x00629; &#x00628;&#x00627;&#x0062d;&#x0062a;&#x00633;&#x00627;&#x00628; &#x00645;&#x0062f;&#x0062f; &#x00627;&#x00644;&#x00639;&#x0062c;&#x00632; (DALYs)&#x0060c; &#x00648;&#x00646;&#x00641;&#x00642;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00631;&#x00639;&#x00627;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00635;&#x0062d;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x00631;&#x0062a;&#x00628;&#x00637;&#x00629; &#x00628;&#x00647;&#x00627;. </p></sec><sec><title>&#x00627;&#x00644;&#x00637;&#x00631;&#x0064a;&#x00642;&#x00629; </title><p>&#x0062a;&#x00634;&#x0064a;&#x00631; &#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631;&#x00627;&#x0062a;&#x00646;&#x00627; &#x00625;&#x00644;&#x00649; &#x00623;&#x00646; &#x00646;&#x00633;&#x00628;&#x00629; &#x00627;&#x00644;&#x00645;&#x0062f;&#x0062e;&#x00648;&#x00644; &#x00627;&#x00644;&#x00623;&#x00633;&#x00627;&#x00633;&#x0064a; &#x00645;&#x00646; &#x00627;&#x00644;&#x00623;&#x0062d;&#x00645;&#x00627;&#x00636; &#x00627;&#x00644;&#x0062f;&#x00647;&#x00646;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x0062a;&#x0062d;&#x00648;&#x00644;&#x00629; &#x00642;&#x00628;&#x00644; &#x00639;&#x00627;&#x00645; 2004 &#x00643;&#x00627;&#x00646;&#x0062a; &#x0062a;&#x00628;&#x00644;&#x0063a; <styled-content style-type="direction" style="direction:ltr;">1.5% </styled-content>&#x00645;&#x00646; &#x00625;&#x0062c;&#x00645;&#x00627;&#x00644;&#x0064a; &#x00645;&#x0062f;&#x0062e;&#x00648;&#x00644; &#x00627;&#x00644;&#x00637;&#x00627;&#x00642;&#x00629;. &#x00644;&#x00630;&#x00644;&#x00643;&#x0060c; &#x00642;&#x00645;&#x00646;&#x00627; &#x00628;&#x00648;&#x00636;&#x00639; &#x00646;&#x00645;&#x00648;&#x00630;&#x0062c; &#x00644;&#x00633;&#x0064a;&#x00627;&#x00633;&#x00629; &#x0062a;&#x0062a;&#x00636;&#x00645;&#x00646; &#x00627;&#x00644;&#x00645;&#x0062f;&#x0062e;&#x00648;&#x00644; &#x00627;&#x00644;&#x00623;&#x00633;&#x00627;&#x00633;&#x0064a; &#x00645;&#x00646; &#x00627;&#x00644;&#x00623;&#x0062d;&#x00645;&#x00627;&#x00636; &#x00627;&#x00644;&#x0062f;&#x00647;&#x00646;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x0062a;&#x0062d;&#x00648;&#x00644;&#x00629; &#x00648;&#x00627;&#x00644;&#x00632;&#x0064a;&#x00648;&#x0062a; &#x00648;&#x00627;&#x00644;&#x0062f;&#x00647;&#x00648;&#x00646; &#x00627;&#x00644;&#x00645;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00645;&#x00629; &#x00644;&#x0062a;&#x0062d;&#x00644; &#x00645;&#x0062d;&#x00644; &#x0062a;&#x00644;&#x00643; &#x00627;&#x00644;&#x00623;&#x0062d;&#x00645;&#x00627;&#x00636; &#x00627;&#x00644;&#x0062f;&#x00647;&#x00646;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x0062a;&#x0062d;&#x00648;&#x00644;&#x00629;&#x0060c; &#x00648;&#x00627;&#x00644;&#x00623;&#x0062b;&#x00631; &#x00627;&#x00644;&#x00625;&#x00643;&#x00644;&#x0064a;&#x00646;&#x0064a;&#x00643;&#x0064a; &#x00644;&#x0062a;&#x00642;&#x00644;&#x0064a;&#x00644; &#x00627;&#x00644;&#x00623;&#x0062d;&#x00645;&#x00627;&#x00636; &#x00627;&#x00644;&#x0062f;&#x00647;&#x00646;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x0062a;&#x0062d;&#x00648;&#x00644;&#x00629; &#x00648;&#x00627;&#x00644;&#x0062a;&#x00643;&#x00627;&#x00644;&#x0064a;&#x00641; &#x00648;&#x00633;&#x00646;&#x00648;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00639;&#x00645;&#x00631; &#x00627;&#x00644;&#x00645;&#x00635;&#x0062d;&#x0062d;&#x00629; &#x00628;&#x00627;&#x0062d;&#x0062a;&#x00633;&#x00627;&#x00628; &#x00645;&#x0062f;&#x0062f; &#x00627;&#x00644;&#x00639;&#x0062c;&#x00632; &#x00627;&#x00644;&#x0062a;&#x0064a; &#x0064a;&#x0062a;&#x00645; &#x0062a;&#x00648;&#x00641;&#x0064a;&#x00631;&#x00647;&#x00627; &#x00628;&#x00633;&#x00628;&#x00628; &#x0062a;&#x0062d;&#x00627;&#x00634;&#x0064a; &#x00648;&#x00642;&#x00627;&#x00626;&#x00639; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x00627;&#x00644;&#x00623;&#x00645;&#x00631;&#x00627;&#x00636; &#x00627;&#x00644;&#x00642;&#x00644;&#x00628;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00648;&#x00639;&#x00627;&#x00626;&#x0064a;&#x00629;. &#x00648;&#x00644;&#x00643;&#x0064a; &#x0064a;&#x0062a;&#x00645; &#x0062d;&#x00633;&#x00627;&#x00628; &#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x00629; &#x00627;&#x00644;&#x00645;&#x00626;&#x00648;&#x0064a;&#x00629; &#x00644;&#x0062a;&#x00642;&#x00644;&#x0064a;&#x00644; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x00627;&#x00644;&#x00623;&#x00645;&#x00631;&#x00627;&#x00636; &#x00627;&#x00644;&#x00642;&#x00644;&#x00628;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00648;&#x00639;&#x00627;&#x00626;&#x0064a;&#x00629;&#x0060c; &#x00641;&#x00642;&#x0062f; &#x00627;&#x0062d;&#x0062a;&#x00633;&#x00628;&#x00646;&#x00627; &#x00645;&#x0062e;&#x00627;&#x00637;&#x00631; &#x0062a;&#x00644;&#x00643; &#x00627;&#x00644;&#x00623;&#x00645;&#x00631;&#x00627;&#x00636; &#x00639;&#x00644;&#x00649; &#x00639;&#x0064a;&#x00646;&#x00629; &#x0062a;&#x00633;&#x0062a;&#x00646;&#x0062f; &#x00625;&#x00644;&#x00649; &#x00634;&#x00631;&#x0064a;&#x0062d;&#x00629; &#x00633;&#x00643;&#x00627;&#x00646;&#x0064a;&#x00629; &#x00642;&#x00628;&#x00644; &#x0062a;&#x00646;&#x00641;&#x0064a;&#x00630; &#x00627;&#x00644;&#x00633;&#x0064a;&#x00627;&#x00633;&#x00629; &#x00648;&#x00628;&#x00639;&#x0062f;&#x00647;&#x00627;. &#x00648;&#x0062a;&#x00645; &#x00648;&#x00636;&#x00639; &#x00646;&#x00645;&#x00627;&#x00630;&#x0062c; &#x00644;&#x00623;&#x0062b;&#x00631; &#x00627;&#x00644;&#x00633;&#x0064a;&#x00627;&#x00633;&#x00627;&#x0062a; &#x00628;&#x00627;&#x0062a;&#x00628;&#x00627;&#x00639; &#x0062b;&#x00644;&#x00627;&#x0062b; &#x00637;&#x00631;&#x00642; &#x00627;&#x00633;&#x0062a;&#x00646;&#x00627;&#x0062f;&#x00627;&#x0064b; &#x00625;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x0063a;&#x0064a;&#x0064a;&#x00631;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00645;&#x0062a;&#x00648;&#x00642;&#x00639;&#x00629;: (1) &#x00641;&#x0064a; &#x00623;&#x00646;&#x00645;&#x00627;&#x00637; &#x0062f;&#x00647;&#x00648;&#x00646; &#x00627;&#x00644;&#x00628;&#x00644;&#x00627;&#x00632;&#x00645;&#x00627;&#x0060c; &#x00648;(2) &#x00641;&#x0064a; &#x00627;&#x00644;&#x0062f;&#x00647;&#x00648;&#x00646; &#x00648;&#x00627;&#x00644;&#x00645;&#x0062d;&#x0062f;&#x0062f;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062d;&#x0064a;&#x00648;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00627;&#x00644;&#x0062a;&#x00647;&#x00627;&#x00628;&#x0064a;&#x00629; (Inflammatory biomarkers&#x0060c; &#x00648;(3) &#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; &#x00627;&#x00644;&#x0062f;&#x00631;&#x00627;&#x00633;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00623;&#x0062a;&#x00631;&#x00627;&#x00628;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00628;&#x00627;&#x00642;&#x0064a;&#x00629; (Prospective cohort studies). &#x00643;&#x00645;&#x00627; &#x00648;&#x00636;&#x00639;&#x00646;&#x00627; &#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631;&#x0064b;&#x00627; &#x00644;&#x00644;&#x00642;&#x0064a;&#x00645;&#x00629; &#x00627;&#x00644;&#x00627;&#x00642;&#x0062a;&#x00635;&#x00627;&#x0062f;&#x0064a;&#x00629; &#x00627;&#x00644;&#x0062d;&#x00627;&#x00644;&#x0064a;&#x00629; &#x00644;&#x00633;&#x00646;&#x00648;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00639;&#x00645;&#x00631; &#x00627;&#x00644;&#x00645;&#x00635;&#x0062d;&#x0062d;&#x00629; &#x00628;&#x00627;&#x0062d;&#x0062a;&#x00633;&#x00627;&#x00628; &#x00645;&#x0062f;&#x0062f; &#x00627;&#x00644;&#x00639;&#x0062c;&#x00632; &#x00648;&#x00645;&#x00627; &#x0064a;&#x00631;&#x0062a;&#x00628;&#x00637; &#x00628;&#x00647;&#x00627; &#x00645;&#x00646; &#x0062a;&#x00643;&#x00627;&#x00644;&#x0064a;&#x00641; &#x00644;&#x00644;&#x00631;&#x00639;&#x00627;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00635;&#x0062d;&#x0064a;&#x00629; &#x00644;&#x00645;&#x00631;&#x00636; &#x00627;&#x00644;&#x00642;&#x00644;&#x00628; &#x00627;&#x00644;&#x00648;&#x00639;&#x00627;&#x00626;&#x0064a; &#x00627;&#x00644;&#x00630;&#x0064a; &#x0062a;&#x00645; &#x0062a;&#x0062d;&#x00627;&#x00634;&#x0064a; &#x00627;&#x00644;&#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x00647;. </p></sec><sec><title>&#x00627;&#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; </title><p>&#x0062a;&#x00634;&#x0064a;&#x00631; &#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631;&#x00627;&#x0062a;&#x00646;&#x00627; &#x00625;&#x00644;&#x00649; &#x00623;&#x00646; &#x00627;&#x00644;&#x0062a;&#x0063a;&#x0064a;&#x0064a;&#x00631;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00645;&#x0062a;&#x00648;&#x00642;&#x00639;&#x00629; &#x00641;&#x0064a; &#x00646;&#x00645;&#x00637; &#x00627;&#x00644;&#x0062f;&#x00647;&#x00648;&#x00646; &#x00633;&#x0064a;&#x00624;&#x0062f;&#x0064a; &#x00625;&#x00644;&#x00649; &#x0062a;&#x0062d;&#x00627;&#x00634;&#x0064a; 301 &#x0062d;&#x00627;&#x00644;&#x00629; &#x00648;&#x00641;&#x00627;&#x00629;&#x0060c; &#x00648;1066 &#x00648;&#x00627;&#x00642;&#x00639;&#x00629; &#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x0062d;&#x00627;&#x00644;&#x00627;&#x0062a; &#x0062d;&#x00627;&#x0062f;&#x00629; &#x00645;&#x00646; &#x00627;&#x00644;&#x00623;&#x00645;&#x00631;&#x00627;&#x00636; &#x00627;&#x00644;&#x00642;&#x00644;&#x00628;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00648;&#x00639;&#x00627;&#x00626;&#x0064a;&#x00629;&#x0060c; &#x00648;&#x00625;&#x00646;&#x00642;&#x00627;&#x00630; 5237 &#x00633;&#x00646;&#x00629; &#x00639;&#x00645;&#x00631; &#x00645;&#x00635;&#x0062d;&#x0062d;&#x00629; &#x00628;&#x00627;&#x0062d;&#x0062a;&#x00633;&#x00627;&#x00628; &#x00645;&#x0062f;&#x0062f; &#x00627;&#x00644;&#x00639;&#x0062c;&#x00632;&#x0060c; &#x00648;17 &#x00645;&#x00644;&#x0064a;&#x00648;&#x00646; &#x0062f;&#x00648;&#x00644;&#x00627;&#x00631; &#x00623;&#x00645;&#x00631;&#x0064a;&#x00643;&#x0064a; &#x00633;&#x00646;&#x00648;&#x0064a;&#x0064b;&#x00627; &#x00645;&#x00646; &#x00646;&#x00641;&#x00642;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00631;&#x00639;&#x00627;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00635;&#x0062d;&#x0064a;&#x00629;. &#x00648;&#x00628;&#x00646;&#x00627;&#x00621;&#x0064b; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00622;&#x0062b;&#x00627;&#x00631; &#x00627;&#x00644;&#x0062c;&#x00627;&#x00646;&#x00628;&#x0064a;&#x00629; &#x00644;&#x00645;&#x0062f;&#x0062e;&#x00648;&#x00644; &#x00627;&#x00644;&#x00623;&#x0062d;&#x00645;&#x00627;&#x00636; &#x00627;&#x00644;&#x0062f;&#x00647;&#x00646;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x0062a;&#x0062d;&#x00648;&#x00644;&#x00629; &#x00627;&#x00644;&#x0062a;&#x0064a; &#x00648;&#x00631;&#x0062f;&#x0062a; &#x0062a;&#x00642;&#x00627;&#x00631;&#x0064a;&#x00631; &#x00628;&#x00634;&#x00623;&#x00646;&#x00647;&#x00627; &#x00641;&#x0064a; &#x00627;&#x00644;&#x0062f;&#x00631;&#x00627;&#x00633;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00623;&#x0062a;&#x00631;&#x00627;&#x00628;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00628;&#x00627;&#x00642;&#x0064a;&#x00629;&#x0060c; &#x00641;&#x00633;&#x0064a;&#x0062a;&#x00645; &#x0062a;&#x0062c;&#x00646;&#x00628; 1517 &#x0062d;&#x00627;&#x00644;&#x00629; &#x00648;&#x00641;&#x00627;&#x00629;&#x0060c; &#x00648;5373 &#x00648;&#x00627;&#x00642;&#x00639;&#x00629; &#x00625;&#x00635;&#x00627;&#x00628;&#x00629; &#x00628;&#x0062d;&#x00627;&#x00644;&#x00627;&#x0062a; &#x0062d;&#x00627;&#x0062f;&#x00629; &#x00645;&#x00646; &#x00627;&#x00644;&#x00623;&#x00645;&#x00631;&#x00627;&#x00636; &#x00627;&#x00644;&#x00642;&#x00644;&#x00628;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00648;&#x00639;&#x00627;&#x00626;&#x0064a;&#x00629;&#x0060c; &#x00648;&#x00625;&#x00646;&#x00642;&#x00627;&#x00630; 26,394 &#x00633;&#x00646;&#x00629; &#x00639;&#x00645;&#x00631; &#x00645;&#x00635;&#x0062d;&#x0062d;&#x00629; &#x00628;&#x00627;&#x0062d;&#x0062a;&#x00633;&#x00627;&#x00628; &#x00645;&#x0062f;&#x0062f; &#x00627;&#x00644;&#x00639;&#x0062c;&#x00632;&#x0060c; &#x00648;87 &#x00645;&#x00644;&#x0064a;&#x00648;&#x00646; &#x0062f;&#x00648;&#x00644;&#x00627;&#x00631; &#x00623;&#x00645;&#x00631;&#x0064a;&#x00643;&#x0064a; &#x00633;&#x00646;&#x00648;&#x0064a;&#x0064b;&#x00627;. </p></sec><sec><title>&#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00646;&#x0062a;&#x00627;&#x0062c; </title><p>&#x0062d;&#x0062a;&#x00649; &#x00641;&#x0064a; &#x00638;&#x00644; &#x00627;&#x00644;&#x00633;&#x0064a;&#x00646;&#x00627;&#x00631;&#x0064a;&#x00648;&#x00647;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00623;&#x00643;&#x0062b;&#x00631; &#x0062a;&#x0062d;&#x00641;&#x00638;&#x0064b;&#x00627;&#x0060c; &#x00641;&#x00642;&#x0062f; &#x00643;&#x00627;&#x00646; &#x00644;&#x00644;&#x0062d;&#x0062f; &#x00645;&#x00646; &#x00645;&#x0062f;&#x0062e;&#x00648;&#x00644; &#x00627;&#x00644;&#x00623;&#x0062d;&#x00645;&#x00627;&#x00636; &#x00627;&#x00644;&#x0062f;&#x00647;&#x00646;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x0062a;&#x0062d;&#x00648;&#x00644;&#x00629; &#x00623;&#x0062b;&#x00631; &#x00643;&#x00628;&#x0064a;&#x00631; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00635;&#x0062d;&#x00629; &#x00627;&#x00644;&#x00639;&#x00627;&#x00645;&#x00629;. &#x00648;&#x00645;&#x00646; &#x00634;&#x00623;&#x00646; &#x00647;&#x00630;&#x00647; &#x00627;&#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; &#x00623;&#x00646; &#x0062a;&#x00641;&#x0064a;&#x0062f; &#x00641;&#x0064a; &#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00645; &#x00627;&#x00644;&#x00645;&#x00639;&#x00644;&#x00648;&#x00645;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00643;&#x00627;&#x00641;&#x0064a;&#x00629; &#x00644;&#x00635;&#x00646;&#x00627;&#x00639; &#x00627;&#x00644;&#x00642;&#x00631;&#x00627;&#x00631; &#x00628;&#x00627;&#x00644;&#x00623;&#x00631;&#x0062c;&#x00646;&#x0062a;&#x0064a;&#x00646; &#x00648;&#x0063a;&#x0064a;&#x00631;&#x00647;&#x00627; &#x00645;&#x00646; &#x00627;&#x00644;&#x00628;&#x00644;&#x0062f;&#x00627;&#x00646; &#x00628;&#x00634;&#x00623;&#x00646; &#x00627;&#x00644;&#x00623;&#x0062b;&#x00631; &#x00627;&#x00644;&#x00645;&#x0062d;&#x0062a;&#x00645;&#x00644; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00635;&#x0062d;&#x00629; &#x00627;&#x00644;&#x00639;&#x00627;&#x00645;&#x00629; &#x00648;&#x00627;&#x00644;&#x00622;&#x0062b;&#x00627;&#x00631; &#x00627;&#x00644;&#x00627;&#x00642;&#x0062a;&#x00635;&#x00627;&#x0062f;&#x0064a;&#x00629; &#x00644;&#x00647;&#x00630;&#x00647; &#x00627;&#x00644;&#x00633;&#x0064a;&#x00627;&#x00633;&#x0064a;&#x00629;. </p></sec></trans-abstract><trans-abstract xml:lang="zh"><title>&#x06458;&#x08981;</title><sec><title>&#x076ee;&#x07684;</title><p>&#x065e8;&#x05728;&#x08bc4;&#x04f30;&#x0963f;&#x06839;&#x05ef7;&#x05883;&#x05185;&#x05173;&#x04e8e;&#x051cf;&#x05c11;&#x04f7f;&#x07528;&#x053cd;&#x05f0f;&#x08102;&#x080aa;&#x09178; (TFA) &#x07684;&#x0653f;&#x07b56;&#x05bf9;&#x051a0;&#x05fc3;&#x075c5; (CHD)&#x03001;&#x06b8b;&#x075be;&#x08c03;&#x06574;&#x0751f;&#x0547d;&#x05e74; (DALY) &#x0548c;&#x076f8;&#x05173;&#x0533b;&#x07597;&#x04fdd;&#x05065;&#x06210;&#x0672c;&#x04ea7;&#x0751f;&#x07684;&#x05f71;&#x054cd;&#x03002;</p></sec><sec><title>&#x065b9;&#x06cd5;</title><p>&#x06211;&#x04eec;&#x04f30;&#x08ba1;&#x051fa; 2004 &#x05e74;&#x04e4b;&#x0524d;&#x05bf9;&#x053cd;&#x05f0f;&#x08102;&#x080aa;&#x09178; (TFA) &#x07684;&#x057fa;&#x051c6;&#x06444;&#x05165;&#x091cf;&#x04e3a;&#x0603b;&#x080fd;&#x091cf;&#x06444;&#x05165;&#x07684; 1.5%&#x03002; &#x06211;&#x04eec;&#x06784;&#x05efa;&#x04e86;&#x0653f;&#x07b56;&#x06a21;&#x0578b;&#x0ff0c;&#x05305;&#x062ec;&#x05bf9;&#x053cd;&#x05f0f;&#x08102;&#x080aa;&#x09178; (TFA) &#x07684;&#x057fa;&#x051c6;&#x06444;&#x05165;&#x091cf;&#x03001;&#x07528;&#x04e8e;&#x04ee3;&#x066ff;&#x04eba;&#x05de5;&#x053cd;&#x05f0f;&#x08102;&#x080aa;&#x09178; (TFA) &#x07684;&#x06cb9;&#x08102;&#x03001;&#x051cf;&#x05c11;&#x04f7f;&#x07528;&#x04eba;&#x05de5;&#x053cd;&#x05f0f;&#x08102;&#x080aa;&#x09178; (TFA) &#x07684;&#x04e34;&#x05e8a;&#x06548;&#x0679c;&#x0ff0c;&#x04ee5;&#x053ca;&#x056e0;&#x09884;&#x09632;&#x051a0;&#x05fc3;&#x075c5; (CHD) &#x04e8b;&#x04ef6;&#x0800c;&#x08282;&#x07ea6;&#x07684;&#x06210;&#x0672c;&#x0548c;&#x06b8b;&#x075be;&#x08c03;&#x06574;&#x0751f;&#x0547d;&#x05e74; (DALY)&#x03002; &#x04e3a;&#x04e86;&#x08ba1;&#x07b97;&#x051a0;&#x05fc3;&#x075c5; (CHD) &#x051cf;&#x05c11;&#x07684;&#x0767e;&#x05206;&#x06bd4;&#x0ff0c;&#x06211;&#x04eec;&#x05728;&#x05b9e;&#x065bd;&#x0524d;&#x0540e;&#x057fa;&#x04e8e;&#x07814;&#x07a76;&#x04eba;&#x07fa4;&#x08ba1;&#x07b97;&#x04e86;&#x051a0;&#x05fc3;&#x075c5; (CHD) &#x098ce;&#x09669;&#x03002; &#x06839;&#x0636e;&#x09884;&#x06d4b;&#x07684;&#x053d8;&#x05316;&#x0ff0c;&#x04ee5;&#x04e09;&#x079cd;&#x065b9;&#x05f0f;&#x06a21;&#x062df;&#x0653f;&#x07b56;&#x07684;&#x05f71;&#x054cd;&#x0ff1a; (i) &#x08840;&#x06d46;&#x04e2d;&#x07684;&#x08840;&#x08102;&#x0ff1b;(ii) &#x08102;&#x08d28;&#x0548c;&#x0708e;&#x06027;&#x06807;&#x08bb0;&#x07269;&#x0ff1b;&#x04ee5;&#x053ca; (iii) &#x0524d;&#x077bb;&#x06027;&#x07fa4;&#x07ec4;&#x07814;&#x07a76;&#x07684;&#x07ed3;&#x0679c;&#x03002; &#x06211;&#x04eec;&#x08fd8;&#x04f30;&#x08ba1;&#x04e86;&#x06b8b;&#x075be;&#x08c03;&#x06574;&#x0751f;&#x0547d;&#x05e74; (DALY) &#x05728;&#x05f53;&#x04e0b;&#x07684;&#x07ecf;&#x06d4e;&#x04ef7;&#x0503c;&#x0ff0c;&#x04ee5;&#x053ca;&#x09884;&#x09632;&#x051a0;&#x05fc3;&#x075c5;&#x07684;&#x076f8;&#x05173;&#x0533b;&#x07597;&#x04fdd;&#x05065;&#x06210;&#x0672c;&#x03002;</p></sec><sec><title>&#x07ed3;&#x0679c;</title><p>&#x06211;&#x04eec;&#x04f30;&#x08ba1;&#x0ff0c;&#x08840;&#x08102;&#x053d8;&#x05316;&#x09884;&#x08ba1;&#x06bcf;&#x05e74;&#x05c06;&#x04f1a;&#x0907f;&#x0514d; 301 &#x04eba;&#x06b7b;&#x04ea1;&#x03001;1066 &#x04f8b;&#x06025;&#x06027;&#x051a0;&#x05fc3;&#x075c5; (CHD) &#x04e8b;&#x04ef6;&#x0548c; 5237 &#x04e2a;&#x06b8b;&#x075be;&#x08c03;&#x06574;&#x0751f;&#x0547d;&#x05e74; (DALY)&#x0ff0c;&#x05e76;&#x053ef;&#x08282;&#x07ea6; 1700 &#x04e07;&#x07f8e;&#x05143; (US$) &#x07684;&#x0533b;&#x07597;&#x04fdd;&#x05065;&#x06210;&#x0672c;&#x03002; &#x057fa;&#x04e8e;&#x0524d;&#x077bb;&#x06027;&#x07fa4;&#x07ec4;&#x07814;&#x07a76;&#x04e2d;&#x06240;&#x062a5;&#x0544a;&#x07684;&#x06444;&#x05165;&#x053cd;&#x05f0f;&#x08102;&#x080aa;&#x09178; (TFA) &#x0540e;&#x04ea7;&#x0751f;&#x07684;&#x04e0d;&#x0826f;&#x05f71;&#x054cd;&#x0ff0c;&#x06bcf;&#x05e74;&#x053ef;&#x09632;&#x06b62; 1517 &#x04eba;&#x06b7b;&#x04ea1;&#x03001;5373 &#x04f8b;&#x06025;&#x06027;&#x051a0;&#x05fc3;&#x075c5; (CHD) &#x04e8b;&#x04ef6;&#x0548c; 26&#x02009;394 &#x04e2a;&#x06b8b;&#x075be;&#x08c03;&#x06574;&#x0751f;&#x0547d;&#x05e74; (DALY)&#x0ff0c;&#x05e76;&#x053ef;&#x08282;&#x07ea6; 8700 &#x04e07;&#x07f8e;&#x05143; (US$)&#x03002;</p></sec><sec><title>&#x07ed3;&#x08bba;</title><p>&#x05373;&#x04f7f;&#x0662f;&#x05728;&#x06700;&#x04e3a;&#x04fdd;&#x05b88;&#x07684;&#x060c5;&#x051b5;&#x04e2d;&#x0ff0c;&#x051cf;&#x05c11;&#x06444;&#x05165;&#x053cd;&#x05f0f;&#x08102;&#x080aa;&#x09178; (TFA) &#x04e5f;&#x053ef;&#x05bf9;&#x0516c;&#x04f17;&#x05065;&#x05eb7;&#x04ea7;&#x0751f;&#x091cd;&#x05927;&#x05f71;&#x054cd;&#x03002; &#x08fd9;&#x04e9b;&#x08c03;&#x067e5;&#x07ed3;&#x0679c;&#x05c06;&#x06709;&#x052a9;&#x04e8e;&#x08ba9;&#x0963f;&#x06839;&#x05ef7;&#x0548c;&#x05176;&#x04ed6;&#x056fd;&#x05bb6;&#x07684;&#x051b3;&#x07b56;&#x05236;&#x05b9a;&#x08005;&#x04e86;&#x089e3;&#x06f5c;&#x05728;&#x07684;&#x0516c;&#x04f17;&#x05065;&#x05eb7;&#x095ee;&#x09898;&#x0548c;&#x08fd9;&#x09879;&#x0653f;&#x07b56;&#x07684;&#x07ecf;&#x06d4e;&#x05f71;&#x054cd;&#x03002;</p></sec></trans-abstract><trans-abstract xml:lang="ru"><title>&#x00420;&#x00435;&#x00437;&#x0044e;&#x0043c;&#x00435;</title><sec><title>&#x00426;&#x00435;&#x0043b;&#x0044c;</title><p>&#x0041e;&#x00446;&#x00435;&#x0043d;&#x00438;&#x00442;&#x0044c; &#x00432;&#x0043e;&#x00437;&#x00434;&#x00435;&#x00439;&#x00441;&#x00442;&#x00432;&#x00438;&#x00435; &#x0043f;&#x00440;&#x00438;&#x0043c;&#x00435;&#x0043d;&#x0044f;&#x00435;&#x0043c;&#x0044b;&#x00445; &#x00432; &#x00410;&#x00440;&#x00433;&#x00435;&#x0043d;&#x00442;&#x00438;&#x0043d;&#x00435; &#x0043f;&#x0043e;&#x0043b;&#x00438;&#x00442;&#x00438;&#x0043a; &#x0043f;&#x0043e; &#x00443;&#x0043c;&#x00435;&#x0043d;&#x0044c;&#x00448;&#x00435;&#x0043d;&#x00438;&#x0044e; &#x0043a;&#x0043e;&#x0043b;&#x00438;&#x00447;&#x00435;&#x00441;&#x00442;&#x00432;&#x00430; &#x00442;&#x00440;&#x00430;&#x0043d;&#x00441;&#x00436;&#x00438;&#x00440;&#x0043d;&#x0044b;&#x00445; &#x0043a;&#x00438;&#x00441;&#x0043b;&#x0043e;&#x00442; &#x00432; &#x0043f;&#x00438;&#x00449;&#x00435; (&#x00422;&#x00416;&#x0041a;) &#x0043d;&#x00430; &#x00440;&#x00430;&#x00437;&#x00432;&#x00438;&#x00442;&#x00438;&#x00435; &#x00438;&#x00448;&#x00435;&#x0043c;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x0043e;&#x00439; &#x00431;&#x0043e;&#x0043b;&#x00435;&#x00437;&#x0043d;&#x00438; &#x00441;&#x00435;&#x00440;&#x00434;&#x00446;&#x00430; (&#x00418;&#x00411;&#x00421;), &#x0043d;&#x00430; &#x0043a;&#x0043e;&#x0043b;&#x00438;&#x00447;&#x00435;&#x00441;&#x00442;&#x00432;&#x0043e; &#x0043b;&#x00435;&#x00442; &#x00436;&#x00438;&#x00437;&#x0043d;&#x00438;, &#x00443;&#x00442;&#x00440;&#x00430;&#x00447;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00432; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x00435; &#x00431;&#x0043e;&#x0043b;&#x00435;&#x00437;&#x0043d;&#x00438;, &#x00438; &#x0043d;&#x00430; &#x00441;&#x0043e;&#x0043f;&#x00443;&#x00442;&#x00441;&#x00442;&#x00432;&#x00443;&#x0044e;&#x00449;&#x00438;&#x00435; &#x00440;&#x00430;&#x00441;&#x00445;&#x0043e;&#x00434;&#x0044b; &#x0043d;&#x00430; &#x00437;&#x00434;&#x00440;&#x00430;&#x00432;&#x0043e;&#x0043e;&#x00445;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x00435;.</p></sec><sec><title>&#x0041c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0044b;</title><p>&#x0041f;&#x0043e; &#x0043d;&#x00430;&#x00448;&#x00438;&#x0043c; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x00430;&#x0043c;, &#x00434;&#x0043e; 2004 &#x00433;&#x0043e;&#x00434;&#x00430; 1,5% &#x0043e;&#x00431;&#x00449;&#x00435;&#x00433;&#x0043e; &#x0043a;&#x0043e;&#x0043b;&#x00438;&#x00447;&#x00435;&#x00441;&#x00442;&#x00432;&#x00430; &#x0043f;&#x00438;&#x00449;&#x00435;&#x00432;&#x0044b;&#x00445; &#x0043a;&#x00430;&#x0043b;&#x0043e;&#x00440;&#x00438;&#x00439; &#x0043f;&#x00440;&#x00438;&#x00445;&#x0043e;&#x00434;&#x00438;&#x0043b;&#x0043e;&#x00441;&#x0044c; &#x0043d;&#x00430; &#x00422;&#x00416;&#x0041a;, &#x00438; &#x0044d;&#x00442;&#x00443; &#x00432;&#x00435;&#x0043b;&#x00438;&#x00447;&#x00438;&#x0043d;&#x00443; &#x0043c;&#x0044b; &#x0043f;&#x00440;&#x00438;&#x0043d;&#x0044f;&#x0043b;&#x00438; &#x00437;&#x00430; &#x00431;&#x00430;&#x00437;&#x0043e;&#x00432;&#x0044b;&#x00439; &#x00443;&#x00440;&#x0043e;&#x00432;&#x00435;&#x0043d;&#x0044c;. &#x0041c;&#x0044b; &#x00440;&#x00430;&#x00437;&#x00440;&#x00430;&#x00431;&#x0043e;&#x00442;&#x00430;&#x0043b;&#x00438; &#x0043c;&#x0043e;&#x00434;&#x00435;&#x0043b;&#x0044c; &#x0043f;&#x0043e;&#x0043b;&#x00438;&#x00442;&#x00438;&#x0043a;&#x00438;, &#x00432;&#x0043a;&#x0043b;&#x0044e;&#x00447;&#x00430;&#x0044e;&#x00449;&#x00443;&#x0044e; &#x00431;&#x00430;&#x00437;&#x0043e;&#x00432;&#x0044b;&#x00439; &#x00443;&#x00440;&#x0043e;&#x00432;&#x00435;&#x0043d;&#x0044c; &#x0043f;&#x0043e;&#x00442;&#x00440;&#x00435;&#x00431;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00422;&#x00416;&#x0041a;, &#x00436;&#x00438;&#x00440;&#x0044b; &#x00438; &#x0043c;&#x00430;&#x00441;&#x0043b;&#x00430;, &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0044b;&#x0043c;&#x00438; &#x0043f;&#x0043b;&#x00430;&#x0043d;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043b;&#x0043e;&#x00441;&#x0044c; &#x00437;&#x00430;&#x0043c;&#x00435;&#x0043d;&#x00438;&#x00442;&#x0044c; &#x00438;&#x00441;&#x0043a;&#x00443;&#x00441;&#x00441;&#x00442;&#x00432;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00435; &#x00422;&#x00416;&#x0041a;, &#x0043a;&#x0043b;&#x00438;&#x0043d;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;&#x00439; &#x0044d;&#x00444;&#x00444;&#x00435;&#x0043a;&#x00442; &#x0043e;&#x00442; &#x00441;&#x0043d;&#x00438;&#x00436;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00443;&#x00440;&#x0043e;&#x00432;&#x0043d;&#x0044f; &#x00422;&#x00416;&#x0041a;, &#x00430; &#x00442;&#x00430;&#x0043a;&#x00436;&#x00435; &#x00443;&#x00440;&#x0043e;&#x00432;&#x00435;&#x0043d;&#x0044c; &#x0044d;&#x0043a;&#x0043e;&#x0043d;&#x0043e;&#x0043c;&#x00438;&#x00438; &#x00438; &#x0043a;&#x0043e;&#x0043b;&#x00438;&#x00447;&#x00435;&#x00441;&#x00442;&#x00432;&#x0043e; &#x00441;&#x0043f;&#x00430;&#x00441;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x0043b;&#x00435;&#x00442; &#x00436;&#x00438;&#x00437;&#x0043d;&#x00438; &#x00432; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x00435; &#x0043f;&#x00440;&#x00435;&#x00434;&#x0043e;&#x00442;&#x00432;&#x00440;&#x00430;&#x00449;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00441;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00435;&#x00432; &#x00418;&#x00411;&#x00421;. &#x00414;&#x0043b;&#x0044f; &#x00440;&#x00430;&#x00441;&#x00447;&#x00435;&#x00442;&#x00430; &#x0043f;&#x00440;&#x0043e;&#x00446;&#x00435;&#x0043d;&#x00442;&#x0043d;&#x0043e;&#x00439; &#x00434;&#x0043e;&#x0043b;&#x00438; &#x00441;&#x0043d;&#x00438;&#x00436;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00418;&#x00411;&#x00421; &#x00431;&#x0044b;&#x0043b;&#x00438; &#x00440;&#x00430;&#x00441;&#x00441;&#x00447;&#x00438;&#x00442;&#x00430;&#x0043d;&#x0044b; &#x00440;&#x00438;&#x00441;&#x0043a;&#x00438; &#x00432;&#x0043e;&#x00437;&#x0043d;&#x00438;&#x0043a;&#x0043d;&#x0043e;&#x00432;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00418;&#x00411;&#x00421; &#x00434;&#x0043b;&#x0044f; &#x0043f;&#x0043e;&#x0043f;&#x00443;&#x0043b;&#x0044f;&#x00446;&#x00438;&#x0043e;&#x0043d;&#x0043d;&#x0043e;&#x00439; &#x00432;&#x0044b;&#x00431;&#x0043e;&#x00440;&#x0043a;&#x00438; &#x00434;&#x0043e; &#x00438; &#x0043f;&#x0043e;&#x00441;&#x0043b;&#x00435; &#x00440;&#x00435;&#x00430;&#x0043b;&#x00438;&#x00437;&#x00430;&#x00446;&#x00438;&#x00438; &#x00432;&#x0044b;&#x00448;&#x00435;&#x00443;&#x0043a;&#x00430;&#x00437;&#x00430;&#x0043d;&#x0043d;&#x0043e;&#x00439; &#x0043f;&#x0043e;&#x0043b;&#x00438;&#x00442;&#x00438;&#x0043a;&#x00438;. &#x0042d;&#x00444;&#x00444;&#x00435;&#x0043a;&#x00442; &#x0043e;&#x00442; &#x0043f;&#x00440;&#x00438;&#x0043c;&#x00435;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043f;&#x0043e;&#x0043b;&#x00438;&#x00442;&#x00438;&#x0043a; &#x0043c;&#x0043e;&#x00434;&#x00435;&#x0043b;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043b;&#x00441;&#x0044f; &#x00442;&#x00440;&#x00435;&#x0043c;&#x0044f; &#x0043f;&#x00443;&#x00442;&#x0044f;&#x0043c;&#x00438; &#x00432; &#x00437;&#x00430;&#x00432;&#x00438;&#x00441;&#x00438;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x0043e;&#x00442; &#x0043f;&#x00440;&#x00435;&#x00434;&#x0043f;&#x0043e;&#x0043b;&#x00430;&#x00433;&#x00430;&#x00435;&#x0043c;&#x0044b;&#x00445; &#x00438;&#x00437;&#x0043c;&#x00435;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x00439;: (i) &#x0043f;&#x0043e; &#x0043f;&#x00440;&#x0043e;&#x00444;&#x00438;&#x0043b;&#x0044f;&#x0043c; &#x0043b;&#x00438;&#x0043f;&#x00438;&#x00434;&#x0043e;&#x00432; &#x00432; &#x0043f;&#x0043b;&#x00430;&#x00437;&#x0043c;&#x00435;, (ii) &#x0043f;&#x0043e; &#x0043b;&#x00438;&#x0043f;&#x00438;&#x00434;&#x00430;&#x0043c; &#x00438; &#x00431;&#x00438;&#x0043e;&#x0043c;&#x00430;&#x00440;&#x0043a;&#x00435;&#x00440;&#x00430;&#x0043c; &#x00432;&#x0043e;&#x00441;&#x0043f;&#x00430;&#x0043b;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x0043f;&#x00440;&#x0043e;&#x00446;&#x00435;&#x00441;&#x00441;&#x00430; &#x00438; (iii) &#x0043f;&#x0043e; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x00430;&#x0043c; &#x0043f;&#x00440;&#x0043e;&#x00441;&#x0043f;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0044b;&#x00445; &#x0043a;&#x0043e;&#x00433;&#x0043e;&#x00440;&#x00442;&#x0043d;&#x0044b;&#x00445; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00439;. &#x0041c;&#x0044b; &#x00442;&#x00430;&#x0043a;&#x00436;&#x00435; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x00438;&#x0043b;&#x00438; &#x00442;&#x00435;&#x0043a;&#x00443;&#x00449;&#x00435;&#x00435; &#x0044d;&#x0043a;&#x0043e;&#x0043d;&#x0043e;&#x0043c;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x0043e;&#x00435; &#x00437;&#x0043d;&#x00430;&#x00447;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00441;&#x0043f;&#x00430;&#x00441;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x0043b;&#x00435;&#x00442; &#x00436;&#x00438;&#x00437;&#x0043d;&#x00438; &#x00438; &#x00443;&#x0043c;&#x00435;&#x0043d;&#x0044c;&#x00448;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00441;&#x0043e;&#x0043f;&#x00443;&#x00442;&#x00441;&#x00442;&#x00432;&#x00443;&#x0044e;&#x00449;&#x00438;&#x00445; &#x00440;&#x00430;&#x00441;&#x00445;&#x0043e;&#x00434;&#x0043e;&#x00432; &#x0043d;&#x00430; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00432; &#x00441;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00435; &#x0043f;&#x00440;&#x00435;&#x00434;&#x0043e;&#x00442;&#x00432;&#x00440;&#x00430;&#x00449;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00438;&#x00448;&#x00435;&#x0043c;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x0043e;&#x00439; &#x00431;&#x0043e;&#x0043b;&#x00435;&#x00437;&#x0043d;&#x00438; &#x00441;&#x00435;&#x00440;&#x00434;&#x00446;&#x00430;.</p></sec><sec><title>&#x00420;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0044b;</title><p>&#x0041f;&#x0043e; &#x0043f;&#x00440;&#x00435;&#x00434;&#x00432;&#x00430;&#x00440;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x0043c; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x00430;&#x0043c;, &#x0043f;&#x00440;&#x00435;&#x00434;&#x0043f;&#x0043e;&#x0043b;&#x00430;&#x00433;&#x00430;&#x00435;&#x0043c;&#x0044b;&#x00435; &#x00438;&#x00437;&#x0043c;&#x00435;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00432; &#x0043f;&#x00440;&#x0043e;&#x00444;&#x00438;&#x0043b;&#x00435; &#x0043b;&#x00438;&#x0043f;&#x00438;&#x00434;&#x0043e;&#x00432; &#x0043f;&#x0043e;&#x00437;&#x00432;&#x0043e;&#x0043b;&#x0044f;&#x00442; &#x0043f;&#x00440;&#x00435;&#x00434;&#x0043e;&#x00442;&#x00432;&#x00440;&#x00430;&#x00442;&#x00438;&#x00442;&#x0044c; 301 &#x00441;&#x0043c;&#x00435;&#x00440;&#x00442;&#x0044c;, 1066 &#x0043e;&#x00441;&#x00442;&#x00440;&#x0044b;&#x00445; &#x00441;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00435;&#x00432; &#x00418;&#x00411;&#x00421;, &#x00441;&#x0043f;&#x00430;&#x00441;&#x00442;&#x00438; 5237 &#x0043b;&#x00435;&#x00442; &#x00436;&#x00438;&#x00437;&#x0043d;&#x00438; &#x00438; &#x00441;&#x0044d;&#x0043a;&#x0043e;&#x0043d;&#x0043e;&#x0043c;&#x00438;&#x00442;&#x0044c; 17 &#x0043c;&#x0043b;&#x0043d; &#x00434;&#x0043e;&#x0043b;&#x0043b;. &#x00421;&#x00428;&#x00410; &#x0043d;&#x00430; &#x00435;&#x00436;&#x00435;&#x00433;&#x0043e;&#x00434;&#x0043d;&#x0044b;&#x00445; &#x00440;&#x00430;&#x00441;&#x00445;&#x0043e;&#x00434;&#x00430;&#x00445; &#x0043d;&#x00430; &#x00437;&#x00434;&#x00440;&#x00430;&#x00432;&#x0043e;&#x0043e;&#x00445;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x00435;. &#x00415;&#x00441;&#x0043b;&#x00438; &#x00438;&#x00441;&#x00445;&#x0043e;&#x00434;&#x00438;&#x00442;&#x0044c; &#x00438;&#x00437; &#x0043d;&#x00435;&#x00431;&#x0043b;&#x00430;&#x00433;&#x0043e;&#x0043f;&#x00440;&#x00438;&#x0044f;&#x00442;&#x0043d;&#x0044b;&#x00445; &#x0043f;&#x0043e;&#x00441;&#x0043b;&#x00435;&#x00434;&#x00441;&#x00442;&#x00432;&#x00438;&#x00439; &#x00443;&#x0043f;&#x0043e;&#x00442;&#x00440;&#x00435;&#x00431;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043f;&#x00438;&#x00449;&#x00435;&#x00432;&#x0044b;&#x00445; &#x00422;&#x00416;&#x0041a;, &#x0043e; &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0044b;&#x00445; &#x00441;&#x0043e;&#x0043e;&#x00431;&#x00449;&#x00430;&#x0043b;&#x0043e;&#x00441;&#x0044c; &#x00432; &#x0043f;&#x00440;&#x0043e;&#x00441;&#x0043f;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0044b;&#x00445; &#x0043a;&#x0043e;&#x00433;&#x0043e;&#x00440;&#x00442;&#x0043d;&#x0044b;&#x00445; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f;&#x00445;, &#x00442;&#x0043e; &#x00435;&#x00436;&#x00435;&#x00433;&#x0043e;&#x00434;&#x0043d;&#x0043e; &#x0043c;&#x0043e;&#x00436;&#x0043d;&#x0043e; &#x00431;&#x00443;&#x00434;&#x00435;&#x00442; &#x0043f;&#x00440;&#x00435;&#x00434;&#x0043e;&#x00442;&#x00432;&#x00440;&#x00430;&#x00442;&#x00438;&#x00442;&#x0044c; 1517 &#x00441;&#x0043c;&#x00435;&#x00440;&#x00442;&#x00435;&#x00439;, 5373 &#x0043e;&#x00441;&#x00442;&#x00440;&#x0044b;&#x00445; &#x00441;&#x0043b;&#x00443;&#x00447;&#x00430;&#x0044f; &#x00418;&#x00411;&#x00421;, &#x00441;&#x0043f;&#x00430;&#x00441;&#x00442;&#x00438; 26 394 &#x00433;&#x0043e;&#x00434;&#x00430; &#x00436;&#x00438;&#x00437;&#x0043d;&#x00438; &#x00438; &#x00441;&#x0044d;&#x0043a;&#x0043e;&#x0043d;&#x0043e;&#x0043c;&#x00438;&#x00442;&#x0044c; 87 &#x0043c;&#x0043b;&#x0043d; &#x00434;&#x0043e;&#x0043b;&#x0043b;. &#x00421;&#x00428;&#x00410; &#x0043d;&#x00430; &#x0043c;&#x00435;&#x00434;&#x00438;&#x00446;&#x00438;&#x0043d;&#x00441;&#x0043a;&#x00438;&#x00445; &#x00440;&#x00430;&#x00441;&#x00445;&#x0043e;&#x00434;&#x00430;&#x00445;.</p></sec><sec><title>&#x00412;&#x0044b;&#x00432;&#x0043e;&#x00434;</title><p>&#x00414;&#x00430;&#x00436;&#x00435; &#x0043f;&#x00440;&#x00438; &#x00441;&#x00430;&#x0043c;&#x0043e;&#x0043c; &#x0043d;&#x00435;&#x00431;&#x0043b;&#x00430;&#x00433;&#x0043e;&#x0043f;&#x00440;&#x00438;&#x0044f;&#x00442;&#x0043d;&#x0043e;&#x0043c; &#x00441;&#x00446;&#x00435;&#x0043d;&#x00430;&#x00440;&#x00438;&#x00438; &#x00443;&#x0043c;&#x00435;&#x0043d;&#x0044c;&#x00448;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00443;&#x0043f;&#x0043e;&#x00442;&#x00440;&#x00435;&#x00431;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00422;&#x00416;&#x0041a; &#x00432; &#x00437;&#x0043d;&#x00430;&#x00447;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00439; &#x0043c;&#x00435;&#x00440;&#x00435; &#x0043f;&#x0043e;&#x00432;&#x0043b;&#x00438;&#x0044f;&#x00435;&#x00442; &#x0043d;&#x00430; &#x00437;&#x00434;&#x0043e;&#x00440;&#x0043e;&#x00432;&#x0044c;&#x00435; &#x0043d;&#x00430;&#x00441;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f;. &#x0042d;&#x00442;&#x00438; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0044b; &#x0043f;&#x0043e;&#x0043c;&#x0043e;&#x00433;&#x00443;&#x00442; &#x00438;&#x0043d;&#x00444;&#x0043e;&#x00440;&#x0043c;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x00442;&#x0044c; &#x0043e;&#x00442;&#x00432;&#x00435;&#x00442;&#x00441;&#x00442;&#x00432;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x0043b;&#x00438;&#x00446; &#x00432; &#x00410;&#x00440;&#x00433;&#x00435;&#x0043d;&#x00442;&#x00438;&#x0043d;&#x00435; &#x00438; &#x00434;&#x00440;&#x00443;&#x00433;&#x00438;&#x00445; &#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00430;&#x00445; &#x0043e; &#x0043f;&#x0043e;&#x00442;&#x00435;&#x0043d;&#x00446;&#x00438;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x0043c; &#x00432;&#x0043e;&#x00437;&#x00434;&#x00435;&#x00439;&#x00441;&#x00442;&#x00432;&#x00438;&#x00438; &#x00442;&#x00430;&#x0043a;&#x0043e;&#x00439; &#x0043f;&#x0043e;&#x0043b;&#x00438;&#x00442;&#x00438;&#x0043a;&#x00438; &#x0043d;&#x00430; &#x00437;&#x00434;&#x0043e;&#x00440;&#x0043e;&#x00432;&#x0044c;&#x00435; &#x0043d;&#x00430;&#x00441;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00438; &#x0043d;&#x00430;&#x00446;&#x00438;&#x0043e;&#x0043d;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x00443;&#x0044e; &#x0044d;&#x0043a;&#x0043e;&#x0043d;&#x0043e;&#x0043c;&#x00438;&#x0043a;&#x00443;.</p></sec></trans-abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Artificial trans fatty acids (TFAs) are produced during the industrial processing of vegetable oils. The main source of such TFAs is partially hydrogenated vegetable oils.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> Consumption of TFAs alters the plasma lipid profile<xref rid="R2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="R3" ref-type="bibr"><sup>3</sup></xref> in such a way that it increases the risk of coronary heart disease (CHD).<xref rid="R4" ref-type="bibr"><sup>4</sup></xref> A 2% increase in energy intake from TFAs may increase the risk for a coronary event by up to 23%.<xref rid="R3" ref-type="bibr"><sup>3</sup></xref> Other potential adverse effects of TFAs include systemic inflammation, endothelial dysfunction, insulin resistance and arrhythmias.<xref rid="R2" ref-type="bibr"><sup>2</sup></xref></p><p>Based on these adverse effects, several countries have implemented policies to reduce industrial TFA consumption,<xref rid="R5" ref-type="bibr"><sup>5</sup></xref> including nutrition guidelines, awareness programmes, voluntary or mandatory labelling of the TFA content of foods and health warning labels. Voluntary or legislated programmes to encourage industry to reformulate food products without TFAs and support the production of healthy alternatives have led to improvements in some countries.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref> Mandatory food labelling in Canada<xref rid="R7" ref-type="bibr"><sup>7</sup></xref> and the United States of America<xref rid="R8" ref-type="bibr"><sup>8</sup></xref> have led some manufacturers to reduce or eliminate artificial TFAs in their products. However, many food products still contain such TFAs, especially when served in restaurants, schools, cafeterias and coffee shops.<xref rid="R9" ref-type="bibr"><sup>9</sup></xref></p><p>In Argentina, before 2004, artificial TFAs were present in most sweet or salty solid snack foods, such as biscuits.<xref rid="R10" ref-type="bibr"><sup>10</sup></xref> Between 2004 and 2014, Argentina implemented several policies to reduce artificial TFAs. After 2004, the industry voluntarily reformulated foods by replacing approximately 40% of TFAs from partially hydrogenated vegetable oils, mainly with TFA-free sunflower oil with high-oleic acid content.<xref rid="R11" ref-type="bibr"><sup>11</sup></xref> Regulations enforcing mandatory labelling of artificial TFAs in food were introduced in 2006.<xref rid="R12" ref-type="bibr"><sup>12</sup></xref> With support from the Pan American Health Organization,<xref rid="R13" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="R14" ref-type="bibr"><sup>14</sup></xref> the Argentine Ministry of Health negotiated with industry to eliminate artificial TFAs. The country&#x02019;s food code was amended,<xref rid="R15" ref-type="bibr"><sup>15</sup></xref> such that, by the end of 2014, industrially-produced TFAs in food should not exceed 2% of total fats in vegetable oils and margarines and 5% of total fats in other foods (<xref ref-type="fig" rid="F1">Fig.&#x000a0;1</xref>).<xref rid="R16" ref-type="bibr"><sup>16</sup></xref></p><fig id="F1" fig-type="figure" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Trans fatty acids regulations in Argentina, 2004&#x02013;2015</p></caption><p>RC: Ministerial Resolution; TFA: trans fatty acids.</p><graphic xlink:href="BLT.14.150516-F1"/></fig><p>Here we estimate the potential reductions in annual CHD events, disability-adjusted life years (DALYs) and associated health-care costs attributable to reductions in artificial TFAs in the diet.</p></sec><sec sec-type="methods"><title>Methods</title><p>The main inputs of the policy model for the analysis were: (i)&#x000a0;the estimated baseline intake of TFAs before 2004; (ii)&#x000a0;the types of alternative oils and fats used to replace TFAs; (iii)&#x000a0;the effects of the improvements in plasma lipid profile on CHD risks and (iv)&#x000a0;the health-care costs and DALYs saved due to averted fatal and nonfatal CHD events. Although our study is not a full economic evaluation, we used the CHEERS statement as a guide for reporting.<xref rid="R17" ref-type="bibr"><sup>17</sup></xref></p><sec><title>Baseline intake of TFAs</title><p>To identify estimates of baseline TFA intake in Argentina and the fats used to improve the dietary fat profile between 2004 and 2014, we conducted a literature search using MEDLINE, Embase, LILACS databases and official documents from the government, academia, industry and other public and private organizations. For the database searches, we used the search string &#x0201c;trans fat OR trans fatty acids OR partially hydrogenated oils OR partially hydrogenated fat AND Argentina&#x0201d;.</p><p>Because TFAs cannot be replaced on a 1:1 basis with other specific fatty acids, the unit of replacement was partially hydrogenated vegetable oils (comprised of various fatty acids, including TFAs). Thus, we evaluated both the total partially hydrogenated vegetable oils consumed and the usual proportion of TFAs in partially hydrogenated vegetable oils during 2004&#x02013;2014. Our search was complemented by a consensus meeting of local experts and decision-makers including officials from the Ministry of Health, epidemiologists, nutritionists, cardiologists and food engineers closely involved with the oils&#x02019; and fats&#x02019; suppliers of TFA replacements. They identified key estimates for the model, including the baseline intake of TFA, the proportion of TFA from ruminants and the replacement fats used by industry. Our central estimate of baseline TFA consumption in 2004 was 1.5% of total energy intake, with a lower limit of 1%<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> and an upper limit of 3%.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref> The most common replacement oil was sunflower oil with high-oleic acid content (base case estimate 42.0%; range: 33.6&#x02013;50.4), followed by interesterified fats (18.0%; range: 14.4&#x02013;21.6) and beef tallow (12:0% range: 9.6&#x02013;14.4; <xref ref-type="table" rid="T1">Table&#x000a0;1</xref>).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Baseline TFA intake and replacements; epidemiological and cost inputs</title></caption><table frame="hsides" rules="groups"><col width="215" span="1"/><col width="147" span="1"/><col width="204" span="1"/><col width="166" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Input</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Base case (range)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Probability distribution</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Source</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>TFA intake related</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">TFA intake before 2004, E%</td><td valign="top" align="center" rowspan="1" colspan="1">1.5 (1.0 to 3.0)</td><td valign="top" align="left" rowspan="1" colspan="1">Normal (mean: base; SD:10% of base)</td><td valign="top" align="left" rowspan="1" colspan="1">Consensus panel of experts<xref rid="R14" ref-type="bibr"><sup>14</sup></xref><sup>,</sup><xref rid="R18" ref-type="bibr"><sup>18</sup></xref><sup>,</sup><xref rid="R19" ref-type="bibr"><sup>19</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ruminant TFA, %</td><td valign="top" align="center" rowspan="1" colspan="1">0.5% of E (0.15 to 0.75)</td><td valign="top" align="left" rowspan="1" colspan="1">(Beta; alpha: 2; beta: 3)</td><td valign="top" align="left" rowspan="1" colspan="1">Consensus panel of experts<xref rid="R19" ref-type="bibr"><sup>19</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">TFA content in PHVO, %</td><td valign="top" align="center" rowspan="1" colspan="1">40.0 (30.0 to 50.0)</td><td valign="top" align="left" rowspan="1" colspan="1">Minimum extreme (min: 30; max: 50; likeliest: 45; scale: 4.5)</td><td valign="top" align="left" rowspan="1" colspan="1">Consensus panel of experts</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Replacement by sunflower oil with high-oleic acid content, %</td><td valign="top" align="center" rowspan="1" colspan="1">42.0 (33.6 to 50.4)</td><td valign="top" align="left" rowspan="1" colspan="1">Normal (min: 0%; max: 100%; mean: 42%; SD: 4%)</td><td valign="top" align="left" rowspan="1" colspan="1">Consensus panel of experts</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Replacement by beef tallow, %</td><td valign="top" align="center" rowspan="1" colspan="1">12.0 (9.6 to 14.4)</td><td valign="top" align="left" rowspan="1" colspan="1">Proportionally adjusted to variations of % HOSO</td><td valign="top" align="left" rowspan="1" colspan="1">Consensus panel of experts</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Replacement by sunflower oil with high-stearic acid content, %</td><td valign="top" align="center" rowspan="1" colspan="1">3.5 (2.8 to 4.2)</td><td valign="top" align="left" rowspan="1" colspan="1">Proportionally adjusted to variations of % HOSO</td><td valign="top" align="left" rowspan="1" colspan="1">Consensus panel of experts</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Replacement by sunflower oil and soybean oil, %</td><td valign="top" align="center" rowspan="1" colspan="1">3.0 (2.4 to 3.6)</td><td valign="top" align="left" rowspan="1" colspan="1">Proportionally adjusted to variations of % HOSO</td><td valign="top" align="left" rowspan="1" colspan="1">Consensus panel of experts</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Replacement by interesterified fats, %</td><td valign="top" align="center" rowspan="1" colspan="1">18.0 (14.4 to 21.6)</td><td valign="top" align="left" rowspan="1" colspan="1">Proportionally adjusted to variations of % HOSO</td><td valign="top" align="left" rowspan="1" colspan="1">Consensus panel of experts</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Replacement by palm oil, %</td><td valign="top" align="center" rowspan="1" colspan="1">10.8 (8.6 to 12.9)</td><td valign="top" align="left" rowspan="1" colspan="1">Proportionally adjusted to variations of % HOSO</td><td valign="top" align="left" rowspan="1" colspan="1">Consensus panel of experts</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Replacement by lauric fats, %</td><td valign="top" align="center" rowspan="1" colspan="1">10.8 (8.6 to 12.9)</td><td valign="top" align="left" rowspan="1" colspan="1">Proportionally adjusted to variations of % HOSO</td><td valign="top" align="left" rowspan="1" colspan="1">Consensus panel of experts</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Epidemiological</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Effects of fats on TC/HDL-C</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Change TFA to &#x02009;SFA</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.031 (&#x02212;0.045 to &#x02212;0.017)</td><td valign="top" align="left" rowspan="1" colspan="1">Normal (min: &#x02212;0.045; max: &#x02212;0.017; mean: &#x02212;0.031; SD: 0.007)</td><td valign="top" align="left" rowspan="1" colspan="1">Estimates from Mozaffarian and Clarke<xref rid="R2" ref-type="bibr"><sup>2</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Change TFA to&#x02009;MUFA</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.054 (&#x02212;0.072 to &#x02212;0.036)</td><td valign="top" align="left" rowspan="1" colspan="1">Normal (min: &#x02212;0.072; max: &#x02212;0.036; mean: &#x02212;0.054; SD: 0.009)</td><td valign="top" align="left" rowspan="1" colspan="1">Estimates from Mozaffarian and Clarke<xref rid="R2" ref-type="bibr"><sup>2</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Change TFA to PUFA</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.067 (&#x02212;0.085 to &#x02212;0.049)</td><td valign="top" align="left" rowspan="1" colspan="1">Normal (min: &#x02212;0.085; max: &#x02212;0.049; mean: &#x02212;0.067; SD: 0.009)</td><td valign="top" align="left" rowspan="1" colspan="1">Estimates from Mozaffarian and Clarke<xref rid="R2" ref-type="bibr"><sup>2</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Change SFA to&#x02009;MUFA</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.029 (&#x02212;0.043 to &#x02212;0.015)</td><td valign="top" align="left" rowspan="1" colspan="1">Normal (min: &#x02212;0.043; max: &#x02212;0.015; mean: &#x02212;0.029; SD: 0.007)</td><td valign="top" align="left" rowspan="1" colspan="1">Estimates from Mozaffarian and Clarke<xref rid="R2" ref-type="bibr"><sup>2</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Change SFA to &#x02009;PUFA</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.035 (&#x02212;0.049 to &#x02212;0.021)</td><td valign="top" align="left" rowspan="1" colspan="1">Normal (min: &#x02212;0.049; max: &#x02212;0.021; mean: &#x02212;0.035; SD: 0.007)</td><td valign="top" align="left" rowspan="1" colspan="1">Estimates from Mozaffarian and Clarke<xref rid="R2" ref-type="bibr"><sup>2</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Change MUFA to &#x02009;PUFA</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.006 (&#x02212;0.020 to 0.008)</td><td valign="top" align="left" rowspan="1" colspan="1">Normal (min: &#x02212;0.020; max: 0.08; mean: &#x02212;0.020; SD :0.007)</td><td valign="top" align="left" rowspan="1" colspan="1">Estimates from Mozaffarian and Clarke<xref rid="R2" ref-type="bibr"><sup>2</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Effect of TFA replacements on other biomarkers (dietary trials)</td><td valign="top" align="center" rowspan="1" colspan="1">2.92 (NA)</td><td valign="top" align="left" rowspan="1" colspan="1">Normal (min: 2.33; max: 3.5; mean: 2.92; SD: 0.292)</td><td valign="top" align="left" rowspan="1" colspan="1">Estimates from Mozaffarian and Clarke<xref rid="R2" ref-type="bibr"><sup>2</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Effect of TFA replacements from cohort studies</td><td valign="top" align="center" rowspan="1" colspan="1">5.04 (NA)</td><td valign="top" align="left" rowspan="1" colspan="1">Normal (min: 4.03; max: 6.05; mean: 5.04; SD: 0.50)</td><td valign="top" align="left" rowspan="1" colspan="1">Estimates from Mozaffarian and Clarke<xref rid="R2" ref-type="bibr"><sup>2</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Case fatality rate AMI men, %</td><td valign="top" align="center" rowspan="1" colspan="1">44.0 (35.2 to 52.8)</td><td valign="top" align="left" rowspan="1" colspan="1">Normal (min: 35.2%; max: 52.8%; mean: 44%; SD: 4.4%)</td><td valign="top" align="left" rowspan="1" colspan="1">Salomon et al.<xref rid="R20" ref-type="bibr"><sup>20</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Case fatality rate AMI women, %</td><td valign="top" align="center" rowspan="1" colspan="1">38.0 (30.4 to 45.6)</td><td valign="top" align="left" rowspan="1" colspan="1">Normal (min: 30.4%; max: 45.6%; mean: 38%; SD: 3.8%)</td><td valign="top" align="left" rowspan="1" colspan="1">Salomon et al.<xref rid="R20" ref-type="bibr"><sup>20</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Case fatality rate ACS men, %</td><td valign="top" align="center" rowspan="1" colspan="1">14.7 (11.7 to 17.6)</td><td valign="top" align="left" rowspan="1" colspan="1">Normal (min: 11.7%; max: 17.6%; mean: 14.7%; SD: 1.5%)</td><td valign="top" align="left" rowspan="1" colspan="1">Estimated from Bazzino et al.<xref rid="R21" ref-type="bibr"><sup>21</sup></xref> and Salomon et al.<xref rid="R20" ref-type="bibr"><sup>20</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Case fatality rate ACS women, %</td><td valign="top" align="center" rowspan="1" colspan="1">12.7 (10.1 to 15.2)</td><td valign="top" align="left" rowspan="1" colspan="1">Normal (min: 10.1%; max: 15.2%; mean: 12.7%; SD: 1.2%)</td><td valign="top" align="left" rowspan="1" colspan="1">Estimated from Bazzino et al.<xref rid="R21" ref-type="bibr"><sup>21</sup></xref> and Salomon et al.<xref rid="R20" ref-type="bibr"><sup>20</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Total AMI deaths (n)</td><td valign="top" align="center" rowspan="1" colspan="1">17&#x000a0;942 (NA)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">National statistics from MoH</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Total CHD deaths (n)</td><td valign="top" align="center" rowspan="1" colspan="1">24&#x000a0;875 (NA)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">National statistics from MoH</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Cost</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cost per AMI event, US$</td><td valign="top" align="center" rowspan="1" colspan="1">5&#x000a0;765 (4&#x000a0;612 to 6&#x000a0;918)</td><td valign="top" align="left" rowspan="1" colspan="1">Normal (min: 0; mean: 5765.4; SD: 576.5)</td><td valign="top" align="left" rowspan="1" colspan="1">Health system costs average<xref rid="R22" ref-type="bibr"><sup>22</sup></xref><sup>&#x02013;</sup><xref rid="R27" ref-type="bibr"><sup>27</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cost per ACS event, US$</td><td valign="top" align="center" rowspan="1" colspan="1">6&#x000a0;416 (5&#x000a0;133 to 7&#x000a0;699)</td><td valign="top" align="left" rowspan="1" colspan="1">Normal (min: 0; mean: 6416; SD: 641.6)</td><td valign="top" align="left" rowspan="1" colspan="1">Health system costs average<xref rid="R22" ref-type="bibr"><sup>22</sup></xref><sup>&#x02013;</sup><xref rid="R27" ref-type="bibr"><sup>27</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Annual costs per follow-up and treatment, US$</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;199 (959 to 1&#x000a0;439)</td><td valign="top" align="left" rowspan="1" colspan="1">Normal (min: 0; mean: 1199; SD: 119.9)</td><td valign="top" align="left" rowspan="1" colspan="1">Health system costs average<xref rid="R22" ref-type="bibr"><sup>22</sup></xref><sup>&#x02013;</sup><xref rid="R27" ref-type="bibr"><sup>27</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Programmatic costs, US$</td><td valign="top" align="center" rowspan="1" colspan="1">129&#x000a0;001 (NA)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">Personal communication (MoH estimates)</td></tr></tbody></table><table-wrap-foot><p>ACS: acute coronary syndrome; AMI: acute myocardial infarction; CHD: coronary heart disease; E: energy intake; HOSO: high-oleic sunflower oil; MoH: ministry of health; MUFA: monounsaturated fatty acids; NA: not applicable; PHVO: partially hydrogenated vegetable oils; PUFA: polyunsaturated fatty acids; SD: standard deviation; SFA: saturated fatty acids; TC/HDL-C: total cholesterol/high-density lipoprotein cholesterol; TFA: trans fatty acids; US$: United States dollars.</p><p>Notes: Discount rates of 5% (range 0&#x02013;10) were used.<xref rid="R28" ref-type="bibr"><sup>28</sup></xref> We used the average conversion rate during 2012, which was US$&#x000a0;1 to 4.55 Argentine dollars.<xref rid="R29" ref-type="bibr"><sup>29</sup></xref></p></table-wrap-foot></table-wrap></sec><sec><title>Changes in lipid profile</title><p>Improvements in the plasma lipid profile were expected to result in improvements in CHD risks. We assessed the relevant changes in plasma lipid profiles and other biomarkers of CHD risk based on meta-analyses of controlled dietary feeding trials.<xref rid="R2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="R4" ref-type="bibr"><sup>4</sup></xref> These estimates were used to drive projections of CHD risks, as outlined below.</p></sec><sec><title>CHD risk</title><p>To estimate reductions in CHD risk in the national population, we adapted a cardiovascular risk calculator, based on the Framingham risk equation and ASSIGN scores.<xref rid="R30" ref-type="bibr"><sup>30</sup></xref> We used individual level data on CHD risk factors from a national prospective cohort study.<xref rid="R31" ref-type="bibr"><sup>31</sup></xref> The study collected baseline data in 2011&#x02013;2012 on age, gender, smoking, systolic blood pressure, diabetes, left ventricular hypertrophy and the ratio total cholesterol (TC)/high-density lipoprotein cholesterol (HDL-C). We combined these results with demographic data for Argentina using the 2010 census to create a national CHD risk profile.<xref rid="R32" ref-type="bibr"><sup>32</sup></xref></p><p>According to the consensus of our expert panel, between 2004 and 2014, most of the partially hydrogenated vegetable oils in the diet were replaced by healthier fats. In 2011&#x02013;2012, when the prospective cohort study took place, 75% had been replaced. We used the observed TC/HDL-C ratio for each person in the 2011&#x02013;2012 cohort study to calculate the expected TC/HDL-C ratios in 2004 and 2014. This calculation was based on the estimated baseline intake of TFA, the established effects of TFA on the TC/HDL-C ratio and the types and percentages of different fats/oils used by industry for replacements. According to the distributions of TC/HDL-C and other risk factors in the population in 2004 and 2014, we calculated the difference in the CHD risk between both years. </p><p>Three alternative scenarios were analysed: (i)&#x000a0;the effects of improved dietary fat profile on the ratio of TC/HDL-C and the relation of this ratio to the incidence of CHD (scenario&#x000a0;1);<xref rid="R33" ref-type="bibr"><sup>33</sup></xref> (ii)&#x000a0;the CHD risk reduction through changes in other biomarkers such as apolipoprotein (apo)&#x000a0;B, ApoA1, lipoprotein&#x000a0;(a), triglycerides and C-reactive protein (scenario&#x000a0;2); and (iii)&#x000a0;the reported relation of TFA intake, substituted for carbohydrate intake, with the incidence of CHD in a pooled analysis of prospective studies and attributed to several pathophysiological effects of TFA (scenario&#x000a0;3).<xref rid="R2" ref-type="bibr"><sup>2</sup></xref></p></sec><sec><title>Mortality from CHD</title><p>We estimated the annual number of deaths caused by CHD using national mortality statistics for 2010. We included deaths coded according to the International Classification of Diseases (ICD-10) as I20&#x02013;I25. We also assumed that 80% of the sudden deaths (ICD-10 code R96) were due to CHD.<xref rid="R34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="R35" ref-type="bibr"><sup>35</sup></xref> We increased the number of CHD deaths by 21.5%, to account for the underreporting of CHD as a cause of death.<xref rid="R36" ref-type="bibr"><sup>36</sup></xref></p><p>The difference in CHD risk predicted by the cardiovascular risk calculator was calibrated to the annual mortality from CHD. We assumed that the reduction in CHD deaths was proportional to the difference in estimated CHD risk. We also assumed that the difference in 10 year-CHD risk was equally distributed in each year of the decade 2004&#x02013;2014, by age and sex.</p></sec><sec><title>Morbidity from CHD</title><p>Total acute CHD events &#x02013; fatal and non-fatal acute myocardial infarctions and acute coronary syndrome &#x02013; were estimated from national data on CHD deaths based upon sex-specific 28 day-CHD case-fatality rate for acute myocardial infarctions in southern Latin America (38% in women; 44% in men).<xref rid="R36" ref-type="bibr"><sup>36</sup></xref> For acute coronary syndrome, we used one-third of the case-fatality rate of acute myocardial infarctions, according to local sources.<xref rid="R21" ref-type="bibr"><sup>21</sup></xref> All values were calibrated by age-sex hospital case-fatality rate in Argentina, obtained from the national hospital discharge registry for the public sector.<xref rid="R37" ref-type="bibr"><sup>37</sup></xref></p></sec><sec><title>Calculation of DALYs</title><p>We calculated DALY using individual equations for years of life lost (YLL) and years of life with disability (YLD) according to the Global Burden of Disease Study.<xref rid="R38" ref-type="bibr"><sup>38</sup></xref> Briefly, YLL were calculated from national health statistics as the difference between local life expectancy and age at death. YLD is the product of disability weight and length of survival with disability for CHD events. Disability weights for acute myocardial infarctions and acute coronary syndrome were considered equal.<xref rid="R20" ref-type="bibr"><sup>20</sup></xref> Survival length was estimated using the software DISMOD II (World Health Organization (WHO), Geneva, Switzerland).<xref rid="R39" ref-type="bibr"><sup>39</sup></xref> Finally, DALYs were reported with discounting at a 5% rate.</p></sec><sec><title>Costs</title><p>Cost inputs for the model were costs of acute CHD events, their follow-up and programmatic costs. A micro-costing approach was undertaken considering a health system perspective. Identification of resources related to CHD events, quantities and utilization rates were obtained from secondary local sources<xref rid="R22" ref-type="bibr"><sup>22</sup></xref><sup>&#x02013;</sup><xref rid="R27" ref-type="bibr"><sup>27</sup></xref> and unit costs were derived from public, social security, and private tariffs of local health insurance institutions.</p><p>Costs of annual management of non-fatal CHD were calculated from the individual's age at the episode to the average Argentine life expectancy, by age and gender, and discounted at a 5% annual rate.<xref rid="R28" ref-type="bibr"><sup>28</sup></xref> Finally, costs borne by the Ministry of Health for the implementation of annual surveillance and monitoring of the compliance of the industry with the regulations were also estimated, and included costs of personnel, food analysis, and onsite training at food companies (Daniel Ferrante, Ministry of Health, personal communication, 2013).</p><p>All costs were converted to United States dollars, corresponding to the exchange rate of 2012.<xref rid="R29" ref-type="bibr"><sup>29</sup></xref></p></sec><sec><title>Sensitivity analyses</title><p>To evaluate parameter uncertainty, we performed sensitivity analyses according to established guidelines.<xref rid="R40" ref-type="bibr"><sup>40</sup></xref> A deterministic sensitivity analysis was first performed to evaluate the uncertainty related to specific parameters and their relative importance, depicted in a tornado analysis (<xref ref-type="fig" rid="F2">Fig.&#x000a0;2</xref>). Ranges used for the parameters were extracted from the published literature or expert opinions. To assess global uncertainty, a probabilistic sensitivity analysis was performed, incorporating the main parameters and their distributions. Uncertainty in results was reported using 95% confidence intervals (CI) based on 1000 Monte Carlo simulations. All model inputs including TFA-related, epidemiological and costs parameters are shown in <xref ref-type="table" rid="T1">Table&#x000a0;1</xref>.</p><fig id="F2" fig-type="figure" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Deterministic sensitivity analysis of the parameters used to estimate the impact of trans fatty acids&#x02019; regulations in Argentina, 2004&#x02013;2014</p></caption><p>AMI: acute myocardial infarction; CHD: coronary heart disease; MUFA: monounsaturated fatty acids; PHVO: partially hydrogenated vegetable oils; PUFA: polyunsaturated fatty acids; SFA: saturated fatty acids; TC/HDL-C: total cholesterol/high-density lipoprotein cholesterol; TFA: trans fatty acids; US$: United States dollars.</p><graphic xlink:href="BLT.14.150516-F2"/></fig></sec></sec><sec sec-type="results"><title>Results</title><p>Mortality, case-fatality and acute coronary events per 100&#x02009;000 population are shown in <xref ref-type="table" rid="T2">Table&#x000a0;2</xref>. Based on an estimated 24&#x02009;875 deaths from CHD in 2010, we estimated 83&#x02009;830 CHD acute events in Argentina in people older than 34 years old. The results reported here assume a baseline consumption of 1.5% of total energy intake as TFA in 2004.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Cardiovascular disease events, Argentina, 2010</title></caption><table frame="hsides" rules="groups"><col width="83" span="1"/><col width="113" span="1"/><col width="77" span="1"/><col width="77" span="1"/><col width="77" span="1"/><col width="100" span="1"/><col width="106" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Event</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">No. of persons at risk<sup>a</sup></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">No. of events</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Incidence per 100&#x02009;000 population</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">No. of deaths<sup>b</sup></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Mortality per 100&#x02009;000 population</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Case-fatality rate,<sup>c</sup> %</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Men</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">AMI</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">23&#x000a0;669</td><td valign="top" align="center" rowspan="1" colspan="1">302.713</td><td valign="top" align="center" rowspan="1" colspan="1">10&#x000a0;414</td><td valign="top" align="center" rowspan="1" colspan="1">133</td><td valign="top" align="center" rowspan="1" colspan="1">44.0</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sudden death</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">867</td><td valign="top" align="center" rowspan="1" colspan="1">11.09</td><td valign="top" align="center" rowspan="1" colspan="1">867</td><td valign="top" align="center" rowspan="1" colspan="1">11</td><td valign="top" align="center" rowspan="1" colspan="1">100.0</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">ACS</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">21&#x000a0;649</td><td valign="top" align="center" rowspan="1" colspan="1">276.87</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x000a0;140</td><td valign="top" align="center" rowspan="1" colspan="1">40</td><td valign="top" align="center" rowspan="1" colspan="1">14.5</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Total</td><td valign="top" align="center" rowspan="1" colspan="1">7&#x000a0;818&#x000a0;921</td><td valign="top" align="center" rowspan="1" colspan="1">46&#x000a0;185</td><td valign="top" align="center" rowspan="1" colspan="1">590.681</td><td valign="top" align="center" rowspan="1" colspan="1">14&#x000a0;421</td><td valign="top" align="center" rowspan="1" colspan="1">184</td><td valign="top" align="center" rowspan="1" colspan="1">31.2</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Women</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">AMI</td><td valign="top" align="left" rowspan="1" colspan="1"> &#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">19&#x000a0;809</td><td valign="top" align="center" rowspan="1" colspan="1">220.08</td><td valign="top" align="center" rowspan="1" colspan="1">7&#x000a0;527</td><td valign="top" align="center" rowspan="1" colspan="1">84</td><td valign="top" align="center" rowspan="1" colspan="1">38.0</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sudden death</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">652</td><td valign="top" align="center" rowspan="1" colspan="1">7.25</td><td valign="top" align="center" rowspan="1" colspan="1">652</td><td valign="top" align="center" rowspan="1" colspan="1">7</td><td valign="top" align="center" rowspan="1" colspan="1">100.0</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">ACS</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">17&#x000a0;184</td><td valign="top" align="center" rowspan="1" colspan="1">190.91</td><td valign="top" align="center" rowspan="1" colspan="1">2&#x000a0;274</td><td valign="top" align="center" rowspan="1" colspan="1">25</td><td valign="top" align="center" rowspan="1" colspan="1">13.2</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Total</td><td valign="top" align="center" rowspan="1" colspan="1">9&#x000a0;000&#x000a0;933</td><td valign="top" align="center" rowspan="1" colspan="1">37&#x000a0;645</td><td valign="top" align="center" rowspan="1" colspan="1">418.24</td><td valign="top" align="center" rowspan="1" colspan="1">10&#x000a0;453</td><td valign="top" align="center" rowspan="1" colspan="1">116</td><td valign="top" align="center" rowspan="1" colspan="1">27.8</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>All</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">AMI</td><td valign="top" align="left" rowspan="1" colspan="1"> &#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">43&#x000a0;478</td><td valign="top" align="center" rowspan="1" colspan="1">258.49</td><td valign="top" align="center" rowspan="1" colspan="1">17&#x000a0;941</td><td valign="top" align="center" rowspan="1" colspan="1">107</td><td valign="top" align="center" rowspan="1" colspan="1">41.3</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sudden death</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;519</td><td valign="top" align="center" rowspan="1" colspan="1">9.04</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;520</td><td valign="top" align="center" rowspan="1" colspan="1">9</td><td valign="top" align="center" rowspan="1" colspan="1">100.0</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">ACS</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">38&#x000a0;833</td><td valign="top" align="center" rowspan="1" colspan="1">2687.53</td><td valign="top" align="center" rowspan="1" colspan="1">5&#x000a0;414</td><td valign="top" align="center" rowspan="1" colspan="1">32</td><td valign="top" align="center" rowspan="1" colspan="1">12.0</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Total</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>16</bold>&#x000a0;<bold>819</bold>&#x000a0;<bold>854</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>83</bold>&#x000a0;<bold>830</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>498.40</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>24</bold>&#x000a0;<bold>875</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>148</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>29.7</bold></td></tr></tbody></table><table-wrap-foot><p>AMI: acute myocardial infarction; ACS: acute coronary syndrome.</p><p><sup>a</sup> Based on 2010 national census.</p><p><sup>b</sup> Reported by Ministry of Health 2010.</p><p><sup>C</sup> Average case-fatality rate of an age-calibrated function based on Salomon et al.<xref rid="R20" ref-type="bibr"><sup>20</sup></xref> and Bazzino et al.<xref rid="R21" ref-type="bibr"><sup>21</sup></xref></p><p>Note: Population older than 34 years.</p></table-wrap-foot></table-wrap><p>Based on the most conservative scenario of TFA replacements only influencing CHD events through changes in the TC/HDL-C ratio (scenario&#x000a0;1), we estimated 301 CHD deaths, 572 acute myocardial infarctions, 1066 acute CHD events and 5237 DALYs averted after 2014, compared with the expected events if the policy had not been implemented (<xref ref-type="table" rid="T3">Table&#x000a0;3</xref>). In addition, more than US$&#x000a0;17 million would be saved annually due to averted acute CHD events and lower costs of chronic treatment and follow-up.</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Annual CHD deaths and CHD acute events and DALYs averted, and costs savings attributable to the full implementation of the policy</title></caption><table frame="hsides" rules="groups"><col width="218" span="1"/><col width="108" span="1"/><col width="95" span="1"/><col width="115" span="1"/><col width="106" span="1"/><col width="115" span="1"/><col width="96" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Scenario</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">No. of CHD deaths averted (95% CI)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">No of AMI deaths averted (95% CI)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">No of acute CHD events averted (95% CI)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Reduction of CHD events, % (95% CI)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">No. of DALYs averted (95% CI)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Total costs saved, million US$ (95% CI)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Scenario 1: Based only on the effect of TFA replacements on the ratio of TC/HDL-C</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Base case &#x02013; 1.5% baseline TFA intake</td><td valign="top" align="center" rowspan="1" colspan="1">301 (233 to 433)</td><td valign="top" align="center" rowspan="1" colspan="1">572 (443 to 823)</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;066 (875 to 1&#x000a0;623)</td><td valign="top" align="center" rowspan="1" colspan="1">1.26 (1.03 to 1.92)</td><td valign="top" align="center" rowspan="1" colspan="1">5&#x000a0;237 (4&#x02009;461 to 8&#x02009;282)</td><td valign="top" align="center" rowspan="1" colspan="1">17.3 (14.5 to 28.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lower limit 1.0%</td><td valign="top" align="center" rowspan="1" colspan="1">151 (109 to 273)</td><td valign="top" align="center" rowspan="1" colspan="1">286 (207 to 519)</td><td valign="top" align="center" rowspan="1" colspan="1">533 (408 to 1&#x000a0;023)</td><td valign="top" align="center" rowspan="1" colspan="1">0.63 (0.48 to 1.21)</td><td valign="top" align="center" rowspan="1" colspan="1">2&#x000a0;619 (2&#x02009;081 to 5&#x02009;220)</td><td valign="top" align="center" rowspan="1" colspan="1">8.6 (6.7 to 17.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Upper limit 3.0%</td><td valign="top" align="center" rowspan="1" colspan="1">752 (571 to 937)</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;429 (1&#x02009;086 to 1&#x02009;781)</td><td valign="top" align="center" rowspan="1" colspan="1">2&#x000a0;663 (2&#x000a0;142 to 3&#x000a0;515)</td><td valign="top" align="center" rowspan="1" colspan="1">3.15 (2.53 to 4.15)</td><td valign="top" align="center" rowspan="1" colspan="1">13&#x02009;087 (10&#x02009;929 to 17&#x02009;941)</td><td valign="top" align="center" rowspan="1" colspan="1">43.2 (35.0 to 62.4)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Scenario 2: Scenario 1 plus the effects of TFA replacements on other CHD biomarkers in controlled trials</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Base case &#x02013; 1.5% baseline TFA intake</td><td valign="top" align="center" rowspan="1" colspan="1">878 (652 to 1&#x02009;328)</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;668 (1&#x02009;238 to 2&#x02009;523)</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x000a0;109 (2&#x000a0;442 to 4&#x000a0;978)</td><td valign="top" align="center" rowspan="1" colspan="1">3.67 (2.89 to 5.88)</td><td valign="top" align="center" rowspan="1" colspan="1">15&#x02009;271(12&#x02009;459 to 25&#x02009;395)</td><td valign="top" align="center" rowspan="1" colspan="1">50.5 (40.5 to 87.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lower limit 1.0%</td><td valign="top" align="center" rowspan="1" colspan="1">439 (307 to 822)</td><td valign="top" align="center" rowspan="1" colspan="1">835 (584 to 1&#x02009;563)</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;555 (1&#x000a0;190 to 2&#x000a0;984)</td><td valign="top" align="center" rowspan="1" colspan="1">1.84 (1.41 to 3.53)</td><td valign="top" align="center" rowspan="1" colspan="1">7&#x000a0;637 (5&#x02009;871 to 15&#x02009;725)</td><td valign="top" align="center" rowspan="1" colspan="1">25.2 (19.7 to 52.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Upper limit 3.0%</td><td valign="top" align="center" rowspan="1" colspan="1">2&#x000a0;192 (1&#x000a0;577 to 2&#x000a0;871)</td><td valign="top" align="center" rowspan="1" colspan="1">4&#x000a0;167 (2&#x000a0;997 to 5&#x02009;458)</td><td valign="top" align="center" rowspan="1" colspan="1">7&#x000a0;764 (6&#x000a0;245 to 10&#x000a0;249)</td><td valign="top" align="center" rowspan="1" colspan="1">9.17 (7.38 to 12.11)</td><td valign="top" align="center" rowspan="1" colspan="1">38&#x02009;163 (30&#x02009;165 to 54&#x02009;987)</td><td valign="top" align="center" rowspan="1" colspan="1">126.&#x02009;2 (102.2 to 182.1)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Scenario 3: Based on the observed relationship of TFA replacements with clinical CHD events in prospective cohort studies</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Base case - 1,5% baseline TFA intake</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;517 (1&#x000a0;118 to 2&#x02009;285)</td><td valign="top" align="center" rowspan="1" colspan="1">2&#x000a0;884 (2&#x000a0;124 to 4&#x02009;343)</td><td valign="top" align="center" rowspan="1" colspan="1">5&#x000a0;373 (4&#x000a0;191 to 8&#x000a0;568)</td><td valign="top" align="center" rowspan="1" colspan="1">6.35 (4.95 to 10.12)</td><td valign="top" align="center" rowspan="1" colspan="1">26&#x02009;394 (21&#x02009;376 to 43&#x02009;713)</td><td valign="top" align="center" rowspan="1" colspan="1">87.3 (69.1 to 150.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lower limit 1.0%</td><td valign="top" align="center" rowspan="1" colspan="1">759 (525 to 1&#x000a0;427)</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x000a0;442 (997 to 2&#x000a0;712)</td><td valign="top" align="center" rowspan="1" colspan="1">2&#x000a0;687 (2&#x000a0;056 to 5&#x000a0;158)</td><td valign="top" align="center" rowspan="1" colspan="1">3.18 (2.43 to 6.09)</td><td valign="top" align="center" rowspan="1" colspan="1">13&#x02009;199 (10&#x02009;031 to 27&#x02009;294)</td><td valign="top" align="center" rowspan="1" colspan="1">43.67 (34.0 to 90.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Upper limit 3.0%</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x000a0;788 (2&#x000a0;708 to 4&#x000a0;944)</td><td valign="top" align="center" rowspan="1" colspan="1">7&#x000a0;202 (5&#x02009;148 to 9&#x000a0;399)</td><td valign="top" align="center" rowspan="1" colspan="1">13&#x000a0;419 (10&#x000a0;794 to 17&#x000a0;713)</td><td valign="top" align="center" rowspan="1" colspan="1">15.86 (12.76 to 20.93)</td><td valign="top" align="center" rowspan="1" colspan="1">65&#x02009;958 (51&#x02009;835 to 94&#x02009;697)</td><td valign="top" align="center" rowspan="1" colspan="1">218.1 (176.6 to 314.7)</td></tr></tbody></table><table-wrap-foot><p>AMI: acute myocardial infarction; CHD: coronary heart disease; CI: confidence interval; DALY: disability-adjusted life-years; TC/HDL-C: total cholesterol/high-density lipoprotein cholesterol; TFA: trans fatty acids; US$: United States dollars.</p><p>Notes: We used the average conversion rate during 2012, which was US$&#x000a0;1 to 4.55 Argentine dollars.<xref rid="R29" ref-type="bibr"><sup>29</sup></xref> Biomarkers included apolipoproteins, triglycerides, lipoprotein&#x000a0;(a) and C-reactive protein.</p></table-wrap-foot></table-wrap><p>When effects of TFA on CHD were calculated considering additional effects on other biomarkers (scenario&#x000a0;2), under the central estimate of 1.5% energy intake of TFA, a total of 3109 acute CHD events, 15&#x02009;271 DALYs, and more than US$&#x000a0;50 million in costs will be averted after 2014. If the effects of TFA on CHD were based on observed relationships with clinical events reported in prospective cohort studies (scenario&#x000a0;3), which may more fully account for the various effects of TFA, 1517 CHD deaths, 2884 acute myocardial infarctions, 5373 acute CHD events and 26&#x02009;394 DALYs were averted, resulting in estimated savings of USD&#x000a0;87 million (<xref ref-type="table" rid="T3">Table&#x000a0;3</xref>). The proportion of events averted by the artificial TFA reduction policy in 2014 ranged from 1.26% (scenario&#x000a0;1) to 6.35% (scenario&#x000a0;3) of total CDH events (<xref ref-type="table" rid="T3">Table&#x000a0;3</xref>). The estimated reductions in CHD were sensitive to the assumed baseline TFA intake in 2004 (<xref ref-type="fig" rid="F2">Fig.&#x000a0;2</xref>).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>Given the estimated 84&#x02009;000 annual CHD events in Argentina, at an annual incidence rate of almost 500 cases per 100&#x02009;000 adults older than 34&#x000a0;years old, the current policy of near elimination of industrial TFA might avert between 1.3% and 6.35% of CHD events each year. The decrease would save between US$&#x000a0;17 million and US$&#x000a0;87 million in management of CHD complications and follow-up. Even in the most conservative scenario, the reduction of TFA intake has a substantial public health impact.</p><p>Although there is limited information about the distribution of TFA intakes in subpopulations in most countries, it is likely that many subgroups, particularly low-income populations, could have mean TFA intakes considerably higher than the population mean.<xref rid="R41" ref-type="bibr"><sup>41</sup></xref> There might be subpopulations that consume more industrially processed foods and fast foods with high-TFA content. Legislative strategies to ban artificial TFAs from foods have been more successful than labelling or education as shown in Austria, Denmark, Iceland, Sweden, Switzerland and USA.<xref rid="R9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="R41" ref-type="bibr"><sup>41</sup></xref><sup>&#x02013;</sup><xref rid="R43" ref-type="bibr"><sup>43</sup></xref> In Denmark, the ban on artificial TFAs is thought to have played some part in the decrease of CHD.<xref rid="R11" ref-type="bibr"><sup>11</sup></xref></p><p>WHO has identified removal of artificial TFAs from the food supply as an intervention with favourable return of invested money to reduce the economic impact of noncommunicable diseases in low- and middle-income countries.<xref rid="R44" ref-type="bibr"><sup>44</sup></xref> However, most such countries have not yet included the restriction of TFAs&#x02019; intake as a policy. Governments have been concerned about the feasibility, achievability and public health effect of removing them from the food supply. Thus, little is known about the potential effects on the reduction of CHD burden and cost savings that could be attributable to the implementation of TFA-reduction policies in these countries. Some middle-income countries such as Brazil,<xref rid="R5" ref-type="bibr"><sup>5</sup></xref> Costa Rica,<xref rid="R5" ref-type="bibr"><sup>5</sup></xref> India<xref rid="R45" ref-type="bibr"><sup>45</sup></xref> and Mexico<xref rid="R5" ref-type="bibr"><sup>5</sup></xref> are following the Argentine example and are introducing policy and surveillance systems to monitor the content of TFA in foods.</p><p>A study modelling a legislative intervention to reduce artificial TFA to 0.5% of total energy intake in the United Kingdom of Great Britain and Northern Ireland, estimated that approximately 2700 deaths annually would be prevented, saving the equivalent of approximately 235 million pounds sterling a year.<xref rid="R46" ref-type="bibr"><sup>46</sup></xref> Another modelling study estimated a similar potential impact of this policy in Ireland.<xref rid="R47" ref-type="bibr"><sup>47</sup></xref> Unlike these studies, our model is based on individual data on CHD risk from an Argentine population-based sample, calibrated with national statistics, as well as with local data on dietary fat profiles. Moreover, our study is modelling the impact of a policy that is being implemented.</p><p>Potential limitations of this study should be considered. First, to calculate CHD risk in Argentina we used a cardiovascular risk calculator.<xref rid="R30" ref-type="bibr"><sup>30</sup></xref> The calculator is based on equations developed a couple of decades ago when the CHD incidence was higher. This could overestimate absolute risk in light of secular trends towards lower CHD risk.<xref rid="R48" ref-type="bibr"><sup>48</sup></xref> On the other hand, these risk equations are widely validated for predicting CHD risk. Overestimation would not likely influence our estimates of proportional risk reduction, since relative risks were calibrated with Argentine absolute risks. Second, we used the global percentage estimates to adjust for underreporting of mortality from CHD. Third, costs of food reformulation by industry were not considered, based on our health system perspective. Yet, potential incremental costs for industry to reduce artificial TFA may be at least partly offset by higher pricing or sales due to marketing advantages.<xref rid="R11" ref-type="bibr"><sup>11</sup></xref> In the USA, switching to newer frying oils that were free of TFA was cost neutral.<xref rid="R38" ref-type="bibr"><sup>38</sup></xref> Fourth, we did not have precise data on baseline TFA, the level of which would influence results. Conversely, our nutritional inputs, particularly those related to the TFA baseline intake before 2004, and the partially hydrogenated vegetable oils&#x02019; replacements used by the industry thereafter, were obtained after a thorough literature search for sources of TFA in Argentina. This information was reviewed by experts to reach consensus on information gaps to derive a reasonable central estimate and appropriate upper and lower bounds.</p><p>In conclusion, our findings suggest that artificial TFA reduction interventions, as an example of a nutritional policy aimed to reach the overall population, have beneficial impact on the total burden of CHD in Argentina. These findings will help inform decision-makers in both Argentina and other countries on the potential public health and economic impact of this policy.</p></sec></body><back><ack><title>Acknowledgements</title><p>We thank the following experts for their invaluable inputs to this work: Mariela Alderete, Lorena Allemandi, Eduardo Dubinsky, Daniel Ferrante, Graciela Gonzalez, Claudio Higa, Raul Mejia, Graciela Peterson, Alicia Rovirosa, Mario Sanchez and Marcelo Tavella.</p></ack><fn-group><title>Funding:</title><fn fn-type="supported-by"><p>This work was carried out with the aid of a grant from the International Development Research Center, Ottawa, Canada. IDRC Project Number: 106881-001.</p></fn></fn-group><fn-group><title>Competing interests:</title><fn fn-type="financial-disclosure"><p>None declared.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><string-name><surname>Heymsfield</surname>
<given-names>SB</given-names></string-name>, <string-name><surname>Darby</surname>
<given-names>PC</given-names></string-name>, <string-name><surname>Muhlheim</surname>
<given-names>LS</given-names></string-name>, <string-name><surname>Gallagher</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Wolper</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Allison</surname>
<given-names>DB</given-names></string-name>. <article-title>The calorie: myth, measurement, and reality.</article-title>
<source>Am J Clin Nutr</source>. <year>1995</year>
<month>11</month>;<volume>62</volume>(<issue>5</issue>) <supplement>Suppl</supplement>:<fpage>1034S</fpage>&#x02013;<lpage>41S</lpage>.<pub-id pub-id-type="pmid">7484918</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><string-name><surname>Mozaffarian</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Clarke</surname>
<given-names>R</given-names></string-name>. <article-title>Quantitative effects on cardiovascular risk factors and coronary heart disease risk of replacing partially hydrogenated vegetable oils with other fats and oils.</article-title>
<source>Eur J Clin Nutr</source>. <year>2009</year>
<month>5</month>;<volume>63</volume>
<issue>Suppl 2</issue>:<fpage>S22</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1038/sj.ejcn.1602976</pub-id><pub-id pub-id-type="pmid">19424216</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><string-name><surname>Mozaffarian</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Katan</surname>
<given-names>MB</given-names></string-name>, <string-name><surname>Ascherio</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Stampfer</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Willett</surname>
<given-names>WC</given-names></string-name>. <article-title>Trans fatty acids and cardiovascular disease.</article-title>
<source>N Engl J Med</source>. <year>2006</year>
<month>4</month>
<day>13</day>;<volume>354</volume>(<issue>15</issue>):<fpage>1601</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra054035</pub-id><pub-id pub-id-type="pmid">16611951</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><string-name><surname>Mozaffarian</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Aro</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Willett</surname>
<given-names>WC</given-names></string-name>. <article-title>Health effects of trans-fatty acids: experimental and observational evidence.</article-title>
<source>Eur J Clin Nutr</source>. <year>2009</year>
<month>5</month>;<volume>63</volume>
<issue>Suppl 2</issue>:<fpage>S5</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1038/sj.ejcn.1602973</pub-id><pub-id pub-id-type="pmid">19424218</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><string-name><surname>Colon-Ramos</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Monge-Rojas</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Campos</surname>
<given-names>H</given-names></string-name>. <article-title>Impact of WHO recommendations to eliminate industrial trans-fatty acids from the food supply in Latin America and the Caribbean.</article-title>
<source>Health Policy Plan</source>. <year>2014</year>;Aug 29(5):529-41.<pub-id pub-id-type="pmid">24150503</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><string-name><surname>Nishida</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Uauy</surname>
<given-names>R</given-names></string-name>. <article-title>WHO Scientific Update on health consequences of trans fatty acids: introduction.</article-title>
<source>Eur J Clin Nutr</source>. <year>2009</year>
<month>5</month>;<volume>63</volume>
<issue>Suppl 2</issue>:<fpage>S1</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1038/ejcn.2009.13</pub-id><pub-id pub-id-type="pmid">19424215</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><string-name><surname>Ratnayake</surname>
<given-names>WM</given-names></string-name>, <string-name><surname>L&#x02019;Abbe</surname>
<given-names>MR</given-names></string-name>, <string-name><surname>Mozaffarian</surname>
<given-names>D</given-names></string-name>. <article-title>Nationwide product reformulations to reduce trans fatty acids in Canada: when trans fat goes out, what goes in?</article-title>
<source>Eur J Clin Nutr</source>. <year>2009</year>
<month>6</month>;<volume>63</volume>(<issue>6</issue>):<fpage>808</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1038/ejcn.2008.39</pub-id><pub-id pub-id-type="pmid">18594558</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><string-name><surname>Van Camp</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Hooker</surname>
<given-names>NH</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>CT</given-names></string-name>. <article-title>Changes in fat contents of US snack foods in response to mandatory trans fat labelling.</article-title>
<source>Public Health Nutr</source>. <year>2012</year>
<month>6</month>;<volume>15</volume>(<issue>6</issue>):<fpage>1130</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1017/S1368980012000079</pub-id><pub-id pub-id-type="pmid">22314147</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><string-name><surname>Angell</surname>
<given-names>SY</given-names></string-name>, <string-name><surname>Silver</surname>
<given-names>LD</given-names></string-name>, <string-name><surname>Goldstein</surname>
<given-names>GP</given-names></string-name>, <string-name><surname>Johnson</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Deitcher</surname>
<given-names>DR</given-names></string-name>, <string-name><surname>Frieden</surname>
<given-names>TR</given-names></string-name>, <etal>et al.</etal>
<article-title>Cholesterol control beyond the clinic: New York City&#x02019;s trans fat restriction.</article-title>
<source>Ann Intern Med</source>. <year>2009</year>
<month>7</month>
<day>21</day>;<volume>151</volume>(<issue>2</issue>):<fpage>129</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-151-2-200907210-00010</pub-id><pub-id pub-id-type="pmid">19620165</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><string-name><surname>Peterson</surname>
<given-names>GAD</given-names></string-name>, <string-name><surname>Espeche</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mesa</surname>
<given-names>M</given-names></string-name>, <string-name><surname>J&#x000e1;uregui</surname>
<given-names>P</given-names></string-name>, <string-name><surname>D&#x000ed;az</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Simi</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>[Trans-fatty acids in food consumed by youth in Argentina.]</article-title>
<source>Arch Argent Pediatr</source>. <year>2004</year>;<volume>102</volume>(<issue>2</issue>):<fpage>102</fpage>&#x02013;<lpage>9</lpage>. <comment>Spanish.</comment></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><string-name><surname>L'Abb&#x000e9;</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Stender</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Skeaff</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Ghafoorunissa</surname></string-name>, <string-name><surname>Tavella</surname>
<given-names>M</given-names></string-name>. <article-title>Approaches to removing trans fats from the food supply in industrialized and developing countries.</article-title>
<source>Eur J Clin Nutr</source>. <year>2009</year>;<volume>63</volume>:<fpage>S50</fpage>&#x02013;<lpage>67</lpage>.<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#x00026;db=PubMed&#x00026;list_uids=19190645&#x00026;dopt=Abstract">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&#x00026;db=PubMed&#x00026;list_uids=19190645&#x00026;dopt=Abstract</ext-link><pub-id pub-id-type="doi">10.1038/ejcn.2009.14</pub-id><pub-id pub-id-type="pmid">19190645</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="book"><source>Resolution No. 149 and Resolution No. 638.</source>
<publisher-loc>Buenos Aires</publisher-loc>: <publisher-name>Secretariat of Policies Regulation and Sanitary Relations, Secretariat of Agriculture Livestock Fisheries and Food</publisher-name>; <year>2005</year>.</mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="web">Trans fat free Americas: Declaration of Rio de Janeiro. Washington: Pan American Health Organization; 2008. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.amro.who.int/English/AD/DPC/NC/transfat-declaration-rio.pdf">http://www.amro.who.int/English/AD/DPC/NC/transfat-declaration-rio.pdf</ext-link> [cited 2014 Feb 10].</mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="web">[Trans fats free Americas: conclusions and recommendations, Washington, 26-27 April 2007.] Washington: Pan American Health Organization; 2007. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.msal.gov.ar/ent/images/stories/ciudadanos/pdf/Grasas_trans_Conclusiones_Task_Force.pdf">http://www.msal.gov.ar/ent/images/stories/ciudadanos/pdf/Grasas_trans_Conclusiones_Task_Force.pdf</ext-link> Spanish. [cited 2014 February 10].</mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="book"><source>Resolution No 137 and Resolution No 941.</source>
<publisher-loc>Buenos Aires</publisher-loc>: <publisher-name>Secretariat of Policies RaSRSoA, Livestock, Fisheries and Food</publisher-name>; <year>2010</year>.</mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="book"><string-name><surname>Bonilla-Chac&#x000ed;n</surname>
<given-names>ME</given-names></string-name>. <source>Promoting healthy living in Latin America and the Caribbean: governance of multisectoral activities to prevent risk factors for noncommunicable diseases.</source>
<publisher-loc>Washington</publisher-loc>: <publisher-name>The World Bank</publisher-name>; <year>2014</year>.</mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><string-name><surname>Husereau</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Drummond</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Petrou</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Carswell</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Moher</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Greenberg</surname>
<given-names>D</given-names></string-name>, <etal>et al.</etal>; <collab>CHEERS Task Force</collab>. <article-title>Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.</article-title>
<source>BMJ</source>. <year>2013</year>;<volume>346</volume>
<issue>mar25 1</issue>:<fpage>f1049</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.f1049</pub-id><pub-id pub-id-type="pmid">23529982</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><string-name><surname>Uicich</surname>
<given-names>RRA</given-names></string-name>, <string-name><surname>Pueyrred&#x000f3;n</surname>
<given-names>P</given-names></string-name>, <string-name><surname>O&#x02019;Donnel</surname>
<given-names>A</given-names></string-name>. <article-title>Estimaci&#x000f3;n del consumo de &#x000e1;cidos grasos trans en la Argentina.</article-title>
<source>Actualizaci&#x000f3;n Nutr</source>. <year>2006</year>;<volume>7</volume>:<fpage>57</fpage>&#x02013;<lpage>65</lpage>.</mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><string-name><surname>Valenzuela</surname>
<given-names>BA</given-names></string-name>. <article-title>&#x000c1;cidos grasos con isometria trans i: su origen y los efectos en salud humana.</article-title>
<source>Rev Chil Nutr</source>. <year>2008</year>;<volume>35</volume>(<issue>3</issue>):<fpage>162</fpage>&#x02013;<lpage>71</lpage>. Spanish. <pub-id pub-id-type="doi">10.4067/S0717-75182008000300001</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><string-name><surname>Salomon</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Vos</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Hogan</surname>
<given-names>DR</given-names></string-name>, <string-name><surname>Gagnon</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Naghavi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mokdad</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal>
<article-title>Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.</article-title>
<source>Lancet</source>. <year>2012</year>
<month>12</month>
<day>15</day>;<volume>380</volume>(<issue>9859</issue>):<fpage>2129</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(12)61680-8</pub-id><pub-id pub-id-type="pmid">23245605</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><string-name><surname>Bazzino</surname>
<given-names>O</given-names></string-name>, <string-name><surname>D&#x000ed;az</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Tajer</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Paviotti</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Mele</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Trivi</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>; <collab>The ECLA Collaborative Group</collab>. <article-title>Clinical predictors of in-hospital prognosis in unstable angina: ECLA 3.</article-title>
<source>Am Heart J</source>. <year>1999</year>
<month>2</month>;<volume>137</volume>(<issue>2</issue>):<fpage>322</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1053/hj.1999.v137.93029</pub-id><pub-id pub-id-type="pmid">9924167</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><string-name><surname>Lowenstein Haber</surname>
<given-names>DM</given-names></string-name>, <string-name><surname>Guardiani</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Pieroni</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Pfister</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Carrizo</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Villegas</surname>
<given-names>ED</given-names></string-name>, <etal>et al.</etal>
<article-title>Realidad de la cirug&#x000ed;a card&#x000ed;aca en la Rep&#x000fa;blica Argentina: Registro CONAREC XVI.</article-title>
<source>Rev Argent Cardiol</source>. <year>2010</year>;<volume>78</volume>:<fpage>228</fpage>&#x02013;<lpage>37</lpage>.</mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><string-name><surname>Gagliardi</surname>
<given-names>JCA</given-names></string-name>. <article-title>Higa C y colab. por los Investigadores del Consejo de Emergencias Cardiovasculares y &#x000c1;rea de Investigaci&#x000f3;n SAC. Infarto agudo de miocardio en la Rep&#x000fa;blica Argentina: An&#x000e1;lisis comparativo de sus caracter&#x000ed;sticas y conductas terap&#x000e9;uticas en los &#x000fa;ltimos 18 a&#x000f1;os. Resultados de las Encuestas SAC.</article-title>
<source>Rev Argent Cardiol</source>. <year>2006</year>;<volume>74</volume>:<fpage>125</fpage>.</mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><string-name><surname>Gagliardi</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>De Abreu</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mariani</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Silverstein</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>De Sagastizabal</surname>
<given-names>DM</given-names></string-name>, <string-name><surname>Salzberg</surname>
<given-names>S</given-names></string-name>, <etal>et al.</etal>
<article-title>Motivos de ingreso, procedimientos, evoluci&#x000f3;n y terap&#x000e9;uticas al alta de 54.000 pacientes ingresados a unidades de cuidados intensivos cardiovasculares en la Argentina: Seis a&#x000f1;os del Registro Epi-Cardio.</article-title>
<source>Rev Argent Cardiol</source>. <year>2012</year>;<volume>80</volume>:<fpage>446</fpage>&#x02013;<lpage>54</lpage>.</mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><string-name><surname>P&#x000e9;rez</surname>
<given-names>GE</given-names></string-name>, <string-name><surname>Costabel</surname>
<given-names>JP</given-names></string-name>, <string-name><surname>Gonz&#x000e1;lez</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Zaidel</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Altamirano</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Schiavone</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>Infarto agudo de miocardio en la Rep&#x000fa;blica Argentina. Registro CONAREC XVII.</article-title>
<source>Rev Argent Cardiol</source>. <year>2013</year>;<volume>81</volume>(<issue>5</issue>):<fpage>390</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.7775/rac.es.v81.i5.1391</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><string-name><surname>Linetzky</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Sarmiento</surname>
<given-names>RA</given-names></string-name>, <string-name><surname>Barcelo</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Lowenstein</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Guardiani</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Feldman</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>Angioplastia coronaria en centros con residencia de cardiolog&#x000ed;a en la Argentina: Estudio CONAREC XIV - &#x000c1;rea de Investigaci&#x000f3;n de la SAC.</article-title>
<source>Rev Argent Cardiol</source>. <year>2007</year>;<volume>75</volume>(<issue>5</issue>):<fpage>249</fpage>&#x02013;<lpage>56</lpage>.</mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="web">Pichon-Riviere ARA, Souto A, Augustovski F. Base de datos de costos sanitarios Argentinos, [Documento T&#x000e9;cnico N&#x000b0;3]. Buenos Aires: Instituto de Efectividad Cl&#x000ed;nica y Sanitaria; 2004. Available from: <ext-link ext-link-type="uri" xlink:href="http://">http://</ext-link><ext-link ext-link-type="uri" xlink:href="http://www.iecs.org.ar">www.iecs.org.ar</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>Spanish. [cited 2015 April 16].</mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><string-name><surname>Augustovski</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Garay</surname>
<given-names>OU</given-names></string-name>, <string-name><surname>Pichon-Riviere</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Rubinstein</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Caporale</surname>
<given-names>JE</given-names></string-name>. <article-title>Economic evaluation guidelines in Latin America: a current snapshot.</article-title>
<source>Expert Rev Pharmacoecon Outcomes Res</source>. <year>2010</year>
<month>10</month>;<volume>10</volume>(<issue>5</issue>):<fpage>525</fpage>&#x02013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1586/erp.10.56</pub-id><pub-id pub-id-type="pmid">20950069</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="web">D&#x000f3;lar estadounidense(USD) Para Peso argentino(ARS) [Internet]. Tipo de Cambio; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://usd.es.fxexchangerate.com/ars/">http://usd.es.fxexchangerate.com/ars/</ext-link> Spanish. [cited 2015 Jun 11].</mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="web">Cardiovascular risk calculator [Internet]. Edinburgh: University of Edinburgh; 2010. Available from: <ext-link ext-link-type="uri" xlink:href="http://cvrisk.mvm.ed.ac.uk/calculator/excelcalc.htm">http://cvrisk.mvm.ed.ac.uk/calculator/excelcalc.htm</ext-link> [cited 2013 March 5].</mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><string-name><surname>Rubinstein</surname>
<given-names>AL</given-names></string-name>, <string-name><surname>Irazola</surname>
<given-names>VE</given-names></string-name>, <string-name><surname>Calandrelli</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Elorriaga</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Gutierrez</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Lanas</surname>
<given-names>F</given-names></string-name>, <etal>et al.</etal>
<article-title>Multiple cardiometabolic risk factors in the Southern Cone of Latin America: A population-based study in Argentina, Chile, and Uruguay.</article-title>
<source>Int J Cardiol</source>. <year>2015</year>
<month>3</month>
<day>15</day>;<volume>183</volume>:<fpage>82</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcard.2015.01.062</pub-id><pub-id pub-id-type="pmid">25662056</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="web">Censo 2010 [Internet]. Buenos Aires: National Institute of Statistics and Census of Argentina INDEC; 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.censo2010.indec.gov.ar/index_cuadros.asp">http://www.censo2010.indec.gov.ar/index_cuadros.asp</ext-link> Spanish. [cited 2014 Feb 10].</mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><string-name><surname>Stampfer</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Sacks</surname>
<given-names>FM</given-names></string-name>, <string-name><surname>Salvini</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Willett</surname>
<given-names>WC</given-names></string-name>, <string-name><surname>Hennekens</surname>
<given-names>CH</given-names></string-name>. <article-title>A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction.</article-title>
<source>N Engl J Med</source>. <year>1991</year>
<month>8</month>
<day>8</day>;<volume>325</volume>(<issue>6</issue>):<fpage>373</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM199108083250601</pub-id><pub-id pub-id-type="pmid">2062328</pub-id></mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="book"><collab>Directorate of Statistics and Health Information</collab>. <publisher-loc>Buenos Aires</publisher-loc>: <publisher-name>Ministry of Health</publisher-name>; <year>2010</year>.</mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><string-name><surname>Myerburg</surname>
<given-names>RJ</given-names></string-name>, <string-name><surname>Junttila</surname>
<given-names>MJ</given-names></string-name>. <article-title>Sudden cardiac death caused by coronary heart disease.</article-title>
<source>Circulation</source>. <year>2012</year>
<month>2</month>
<day>28</day>;<volume>125</volume>(<issue>8</issue>):<fpage>1043</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.023846</pub-id><pub-id pub-id-type="pmid">22371442</pub-id></mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="journal"><string-name><surname>Forouzanfar</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Moran</surname>
<given-names>AE</given-names></string-name>, <string-name><surname>Flaxman</surname>
<given-names>AD</given-names></string-name>, <string-name><surname>Roth</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Mensah</surname>
<given-names>GA</given-names></string-name>, <string-name><surname>Ezzati</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>Assessing the global burden of ischemic heart disease, part 2: analytic methods and estimates of the global epidemiology of ischemic heart disease in 2010.</article-title>
<source>Glob Heart</source>. <year>2012</year>
<month>12</month>
<day>1</day>;<volume>7</volume>(<issue>4</issue>):<fpage>331</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.gheart.2012.10.003</pub-id><pub-id pub-id-type="pmid">23505617</pub-id></mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="book"><collab>Direcci&#x000f3;n de Estad&#x000ed;sticas e Informaci&#x000f3;n en Salud</collab>. <article-title>Base de datos de egresos hospitalarios.</article-title>
<publisher-loc>Buenos Aires</publisher-loc>: <publisher-name>Ministerio de Salud</publisher-name>; <year>2008</year>
<comment>Spanish</comment>.</mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><string-name><surname>Murray</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Acharya</surname>
<given-names>AK</given-names></string-name>. <article-title>Understanding DALYs (disability-adjusted life years).</article-title>
<source>J Health Econ</source>. <year>1997</year>
<month>12</month>;<volume>16</volume>(<issue>6</issue>):<fpage>703</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/S0167-6296(97)00004-0</pub-id><pub-id pub-id-type="pmid">10176780</pub-id></mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="web">Health statistics and information systems. Geneva: World Health Organization; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/healthinfo/global_burden_disease/tools_software/en/">http://www.who.int/healthinfo/global_burden_disease/tools_software/en/</ext-link> [cited 2014 March 10].</mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="journal"><string-name><surname>Briggs</surname>
<given-names>AH</given-names></string-name>, <string-name><surname>Weinstein</surname>
<given-names>MC</given-names></string-name>, <string-name><surname>Fenwick</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Karnon</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Sculpher</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Paltiel</surname>
<given-names>AD</given-names></string-name>; <collab>ISPOR-SMDM Modeling Good Research Practices Task Force</collab>. <article-title>Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6.</article-title>
<source>Med Decis Making</source>. <year>2012</year>
<season>Sep-Oct</season>;<volume>32</volume>(<issue>5</issue>):<fpage>722</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1177/0272989X12458348</pub-id><pub-id pub-id-type="pmid">22990087</pub-id></mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="journal"><string-name><surname>Astrup</surname>
<given-names>A</given-names></string-name>. <article-title>The trans fatty acid story in Denmark.</article-title>
<source>Atheroscler Suppl</source>. <year>2006</year>
<month>5</month>;<volume>7</volume>(<issue>2</issue>):<fpage>43</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosissup.2006.04.010</pub-id><pub-id pub-id-type="pmid">16723283</pub-id></mixed-citation></ref><ref id="R42"><label>42</label><mixed-citation publication-type="journal"><string-name><surname>O&#x02019;Keeffe</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Kabir</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>O&#x02019;Flaherty</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Walton</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Capewell</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Perry</surname>
<given-names>IJ</given-names></string-name>. <article-title>Modelling the impact of specific food policy options on coronary heart disease and stroke deaths in Ireland.</article-title>
<source>BMJ Open</source>. <year>2013</year>;<volume>3</volume>(<issue>7</issue>):<fpage>e002837</fpage>.<pub-id pub-id-type="pmid">23824313</pub-id></mixed-citation></ref><ref id="R43"><label>43</label><mixed-citation publication-type="journal"><string-name><surname>Downs</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Thow</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Leeder</surname>
<given-names>SR</given-names></string-name>. <article-title>The effectiveness of policies for reducing dietary trans fat: a systematic review of the evidence.</article-title>
<source>Bull World Health Organ</source>. <year>2013</year>
<month>4</month>
<day>1</day>;<volume>91</volume>(<issue>4</issue>):<fpage>262</fpage>&#x02013;<lpage>9H</lpage>. <pub-id pub-id-type="doi">10.2471/BLT.12.111468</pub-id><pub-id pub-id-type="pmid">23599549</pub-id></mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="web">World Economic Forum, World Health Organization. From burden to &#x0201c;best buys&#x0201d;: reducing the economic impact of non-communicable diseases in low- and middle-income countries. Geneva: World Economic Forum; 2011. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/nmh/publications/best_buys_summary.pdf">http://www.who.int/nmh/publications/best_buys_summary.pdf</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>[cited 2015 April 16].</mixed-citation></ref><ref id="R45"><label>45</label><mixed-citation publication-type="journal"><string-name><surname>Downs</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Thow</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Ghosh-Jerath</surname>
<given-names>S</given-names></string-name>, <string-name><surname>McNab</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Reddy</surname>
<given-names>KS</given-names></string-name>, <string-name><surname>Leeder</surname>
<given-names>SR</given-names></string-name>. <article-title>From Denmark to Delhi: the multisectoral challenge of regulating trans fats in India.</article-title>
<source>Public Health Nutr</source>. <year>2013</year>
<month>12</month>;<volume>16</volume>(<issue>12</issue>):<fpage>2273</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1017/S1368980012004995</pub-id><pub-id pub-id-type="pmid">23164094</pub-id></mixed-citation></ref><ref id="R46"><label>46</label><mixed-citation publication-type="journal"><string-name><surname>Barton</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Andronis</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Briggs</surname>
<given-names>A</given-names></string-name>, <string-name><surname>McPherson</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Capewell</surname>
<given-names>S</given-names></string-name>. <article-title>Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study.</article-title>
<source>BMJ</source>. <year>2011</year>;<volume>343</volume>
<issue>jul28 1</issue>:<fpage>d4044</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.d4044</pub-id><pub-id pub-id-type="pmid">21798967</pub-id></mixed-citation></ref><ref id="R47"><label>47</label><mixed-citation publication-type="journal"><string-name><surname>O&#x02019;Keeffe</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Kabir</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>O&#x02019;Flaherty</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Walton</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Capewell</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Perry</surname>
<given-names>IJ</given-names></string-name>. <article-title>Modelling the impact of specific food policy options on coronary heart disease and stroke deaths in Ireland.</article-title>
<source>BMJ Open</source>. <year>2013</year>;<volume>3</volume>(<issue>7</issue>):<fpage>e002837</fpage>.<pub-id pub-id-type="pmid">23824313</pub-id></mixed-citation></ref><ref id="R48"><label>48</label><mixed-citation publication-type="journal"><string-name><surname>de Fatima Marinho de Souza</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Gawryszewski</surname>
<given-names>VP</given-names></string-name>, <string-name><surname>Ordu&#x000f1;ez</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Sanhueza</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Espinal</surname>
<given-names>MA</given-names></string-name>. <article-title>Cardiovascular disease mortality in the Americas: current trends and disparities.</article-title>
<source>Heart</source>. <year>2012</year>
<month>8</month>;<volume>98</volume>(<issue>16</issue>):<fpage>1207</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1136/heartjnl-2012-301828</pub-id><pub-id pub-id-type="pmid">22826558</pub-id></mixed-citation></ref></ref-list></back></article>